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ABSTRACT 
 
Structural Basis of Viral RNA Recognition by RIG-I-Like Receptors. (August 2012) 
Cheng Lu, B.S., Nankai University, China 
Chair of Advisory Committee: Dr. Pingwei Li 
 
 RIG-I-like receptors (RLRs), RIG-I, MDA5, and LGP2, are a family of innate 
immune receptors that recognize viral RNA in the cytoplasm and initiate antiviral 
responses including the induction of type I interferons and other pro-inflammatory 
cytokines. All three proteins have both an RNA helicase domain with ATPase activity 
and a C-terminal domain (CTD) which is responsible for RNA binding. RIG-I and 
MDA5 also have two tandem caspase activation and recruitment domains (CARDs) at 
the N-terminus which are involved in downstream signaling.  
To understand the structural basis of viral RNA recognition by the RLRs, 
especially RIG-I, we have performed extensive biochemical studies to determine the 
binding properties of RIG-I with different forms of RNA, including dsRNA with and 
without 5'-triphosphate (5'-ppp) groups, and 5'-ppp ssRNA. RIG-I CTD binds to these 
forms of RNA, and exhibits the highest affinity for 5'-ppp dsRNA. We also determined 
the crystal structures of RIG-I CTD in complex with dsRNA with and without 5'-ppp by 
X-ray crystallography. The structures showed that RIG-I recognizes the termini of the 
dsRNA and interacts with the two types of RNA in different orientations. By comparing 
these complex structures together with mutagenesis studies, we conclude that RIG-I 
 iv 
CTD is a versatile binding module capable of recognizing different RNA ligands. 
Similar but partially differing sets of residues are involved in the recognition of dsRNA 
with and without 5'-ppp. Mutations of key residues at the RNA binding surface also 
abolished RIG-I signaling in cells.  
In order to compare the RIG-I/RNA interactions with other RLRs, we also 
determined the dsRNA binding surface of MDA5 CTD by NMR titration studies. MDA5 
CTD has a similar binding surface to that of RIG-I CTD, however with slightly different 
surface electrostatic potentials which indicate different interactions with RNA. This may 
explain how MDA5 senses differing types of viruses compared to RIG-I.  
The current RIG-I activation model suggests that after stimulation by RNA 
binding, RIG-I undergoes an ATP-dependent conformational change, exposing the 
CARDs for downstream signaling. To understand the critical role that the helicase 
domain plays in RIG-I activation by structural approach, we also attempted to crystallize 
the dsRNA-bound helicase domain together with CTD. 
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NOMENCLATURE 
 
A Alanine 
ADAR1 Adenosine deaminase acting on RNA-1 
ADP Adenosine-5'-diphosphate 
AIDS Acquired immune deficiency syndrome 
AMP-PNP Adenosine 5'-(β,γ-imido)triphosphate 
APOBEC3G Apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide- 
  like 3G 
Arg Arginine 
Asp Aspartate 
ASU Asymmetric unit 
ATF  Activating transcription factor 
ATP  Adenosine-5'-triphosphate 
ATPase  Adenosine triphosphatase 
AUC  Analytical ultracentrifugation 
BIR  Baculovirus inhibitor of apoptosis repeat 
C  Cysteine 
CARD  Caspase activation and recruitment domain 
Cardif  CARD adaptor inducing interferon-β 
cDNA  Complementary deoxyribonucleic acid 
CpG  Cytosine-phosphate-guanine 
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CTD  Carboxyl-terminal domain 
Cys  Cysteine 
D  Aspartate 
DC  Dendritic cell 
DEN  Dengue virus 
DNA  Deoxyribonucleic acid 
DTT  Dithiothreitol 
dsDNA  Double-stranded deoxyribonucleic acid 
dsRNA  Double-stranded ribonucleic acid 
E  Glutamate 
E. coli  Escherichia coli 
EDTA  Ethylenediaminetetraacetic acid 
EGCG  Epigallocatechin-3-gallate 
elF2α  E74-like factor 2α 
EMCV  Encephalomyocarditis virus 
EMSA  Electrophoretic mobility shift assay 
EtBr  Ethidium bromide 
F  Phenylalanine 
FADD  Fas-associated protein with death domain 
Glu  Glutamate 
H  Histidine 
HD  Helicase domain 
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HEK  Human embryonic kidney 
HEPES  4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
His  Histidine 
HSQC  Heteronuclear single quantum correlation 
IFN  Interferon 
IFNR  Interferon receptor 
IKK  Inhibitor of κB kinase 
IL  Interleukin 
Ile  Isoleucine 
IL-1R  Interleukin-1 receptor 
IPS-1  Interferon promoter stimulator 1 
IPP  Inorganic pyrophosphatase 
IPTG  Isopropyl-β-D-1-thiogalactopyranoside 
IRF  Interferon regulatory factor 
ISRE  Interferon-stimulated response element 
JEV  Japanese encephalitis virus 
K  Lysine 
LB  Luria Bertani broth 
Leu  Leucine 
LGP2  Laboratory of genetics and physiology 2 
LPS  Lipopolysaccharide 
LRR  Leucine rich repeat 
 x 
Lys  Lysine 
mAb  Monoclonal antibody 
MAVS  Mitochondrial antiviral signaling protein 
MDA5  Melanoma differentiation-associated gene 5 
mRNA  Messenger ribonucleic acid 
MyD88  Myeloid differentiation primary response gene 88 
NCS  Non-crystallography symmetry 
NDV  Newcastle disease virus 
NF-κB  Nuclear factor κB 
NK  Natural killer cell 
NLR  Nucleotide-oligomerization-domain-like receptor 
NMR  Nuclear magnetic resonance 
OAS  2'-5'-Oligoadenylate synthetase 
PAGE  Polyacrylamide gel electrophoresis 
PAMP  Pathogen-associated molecular pattern 
PCR  Polymerase chain reaction 
PDB  Protein data bank 
pDC  Plasmacytoid dendritic cell 
PEG  Polyethylene glycol 
Phe  Phenylalanine 
PKR  Protein kinase R 
PMSF  Phenylmethylsulfonyl fluoride 
 xi 
Poly I:C  Polyinosinic:polycytidylic acid 
pp  Diphosphate 
ppp  Triphosphate 
PRR  Pattern recognition receptor 
PYD  Pyrin domain 
R  Arginine 
RIG-I  Retinoic acid-inducible gene-I 
RLR  RIG-I-like receptor 
r.m.s.d.  Root mean square deviation 
RNA  Ribonucleic acid 
RNAi  Ribonucleic acid interference 
RNase  Ribonuclease 
rNTP  Ribonucleoside triphosphate 
rRNA  Ribosomal ribonucleic acid 
S  Serine 
SAP  Shrimp alkaline phosphatase 
SARS  Severe acute respiratory syndrome 
Sc  Shape correlation statistics 
SDS  Sodium dodecyl sulfate 
Ser  Serine 
SeV  Sendai virus 
SF2  Superfamily 2 
 xii 
Sf9  Spodoptera frugiperda 9 
SPR  Surface plasmon resonance 
ssRNA  Single-stranded ribonucleic acid 
TBK1  TANK-binding kinase 1 
TIR  Toll/IL-1R 
TIRAP TIR-domain-containing adaptor protein 
TLR  Toll-like Receptor 
TRADD  Tumor necrosis factor receptor type 1-associated death domain  
 protein 
TRAF3  Tumor necrosis factor receptor-associated factor 3 
TRIF  TIR-domain-containing adapter inducing interferon-β 
Tris  2-Amino-2-hydroxymethyl-1,3-propanediol 
tRNA Transfer ribonucleic acid 
Trp  Tryptophan 
Tyr  Tyrosine 
VISA  Virus-induced signaling adapter 
VSV  Vesicular stomatitis virus 
X  Any amino acid residue 
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CHAPTER I 
INTRODUCTION  
 
The innate immune system and pattern recognition receptors  
Both animals and plants are constantly threatened by the invasion of 
microorganisms including bacteria, viruses, fungi, and parasites, which cause many 
kinds of infectious diseases. Therefore immune defense systems have been developed to 
combat and eliminate infective pathogens (1,2). The mammalian immune system 
effectively fights against pathogens through the cooperation of two branches, innate and 
adaptive (acquired) immunities. The innate immunity provides the first line of host 
defense against pathogens at the early stage of infection, with contributions from 
macrophages, dendritic cells (DCs), mast cells, neutrophils, eosinophils, and natural 
killer (NK) cells, etc. (3). Adaptive immunity is involved in the elimination of pathogens 
in later phases of infection as well as the generation of lasting immunological memory. It 
is characterized by specific recognition which is achieved by B and T lymphocytes 
bearing an indefinite number of antigen-specific receptors generated by gene 
rearrangement. The adaptive immune responses are relatively slow processes that often 
require days or weeks to reach optimal effects. During this period, the innate immune 
response plays a critical role in controlling infections. It also initiates and subsequently 
directs adaptive immune responses (4). 
 
____________ 
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 Although the innate immune system lacks the fine specificity of adaptive 
immunity that is necessary to produce immunological memory, it is not completely 
nonspecific. It is able to discriminate between noninfectious “self” and infectious “non-
self”. This is achieved by utilizing a limited number of germline-encoded pattern 
recognition receptors (PRRs) that are constitutively expressed in all cells of a given type, 
either on the cell surface, in intracellular compartments, or secreted into the bloodstream 
and tissue fluids (5). They recognize specific microbial components which are highly 
conserved and are essential for the survival or pathogenicity of the microorganism, such 
as flagellin, sugars, or the cell wall components peptidoglycan and lipopolysaccharide 
(LPS). These are known as pathogen-associated molecular patterns (PAMPs) because 
they are shared by large groups of pathogens but do not exist in the host organism. The 
binding of PAMPs by PRRs results in very rapid responses, while the adaptive immune 
response requires a delay for the clonal expansion of lymphocytes. Once activated, the 
PRRs initiate the pro-inflammatory signaling pathways, leading to the secretion of 
humoral factors known as cytokines and chemokines, inducing the expression of 
adhesion and costimulatory molecules in order to recruit immune cells to the site of 
infection and to trigger the adaptive immune response (6). 
 Several types of PRRs have been identified. They can be classified as membrane-
bound PRRs, cytoplasmic PRRs, and secreted PRRs. For example, macrophage mannose 
receptor and macrophage scavenger receptor are cell surface receptors functioning as 
PRRs (7,8), while serum amyloid protein, mannan-binding lectin, and C-reactive protein 
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are secreted PRRs produced by the liver during the acute phase response at the early 
stage of infection (7,9). 
 The most intensely studied and probably the best characterized PRRs are the 
mammalian Toll-like receptors (TLRs) that are homologues of Drosophila Toll. These 
are a family of membrane-bound receptors localizing either to the cell surface or to 
endosomal compartments. TLRs are type I integral membrane glycoproteins 
characterized by the extracellular domains containing multiple leucine-rich-repeat (LRR) 
motifs that form a horseshoe fold, and a cytoplasmic signaling domain homologous to 
that of the interleukin-1 receptor (IL-1R), termed the Toll/IL-1R homology (TIR) 
domain (10). Ten different TLRs have been identified in humans and twelve in mice (11-
13), detecting various ligands including lipids (TLR1, TLR2, and TLR6), flagellin 
(TLR5), double-stranded (ds) viral RNA (TLR3), single-stranded (ss) viral RNA 
(TLR7/TLR8), and bacterial DNA (TLR9). Current models assume that TLRs are 
activated through a ligand-induced dimerization that brings the cytosolic TIR domains in 
close proximity, which enables the recruitment of adaptor proteins, such as MyD88, 
TRIF, and TIRAP, for downstream signaling (14). 
 Some pathogens can gain access to the intracellular compartments, such as the 
cytosol. There are also some cytosolic PRRs, e.g. the nucleotide oligomerization domain 
(NOD)-like receptors (NLRs) and RIG-I-like receptors (RLRs), which can detect these 
intracellular pathogens and induce responses that block their replication. The NLRs are 
multidomain proteins with a tripartite architecture containing C-terminal LRRs for 
ligand sensing, a central nucleotide-binding NACHT domain whose oligomerization is 
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necessary for protein activation, and an N-terminal effector domain which can be a 
caspase activation and recruitment domain (CARD), pyrin domain (PYD), or 
baculovirus IAP (inhibitor of apoptosis) repeat (BIR) domain (6). PYDs and CARDs are 
structurally related and belong to the death-fold domain superfamily whose members are 
frequently found in pathways leading to the activation of caspases or the nuclear factor 
κB (NF-κB) (15). The death-fold domains are characterized by six α helices that are 
tightly packed in a Greek key fold and form trimers or dimers with other members of the 
same subfamily (e.g. either PYD/PYD or CARD/CARD interactions) to mediate signal 
transduction to downstream targets. 
 
Critical roles of type I interferons in innate immunity toward viral infection 
 Viral pathogens have been discovered in all species from bacteria to mammals. 
Viruses cause many kinds of infectious diseases such as the common cold, influenza, 
measles, rabies, hepatitis, many forms of diarrhea, yellow fever, polio, smallpox, SARS, 
and AIDS. A number of viral diseases such as polio and smallpox have almost been 
eliminated by successful immunization in early childhood. However, many other viral 
diseases such as hepatitis and AIDS are still major threats to human health, especially for 
people in the developing world. 
 Viral infections provoke various host responses, including early innate and 
subsequent adaptive immune responses. For innate responses, some PRRs are 
genetically programmed to detect a wide range of viral infections and activate the 
induction of cytokines and chemokines. The most important cytokines in viral infection 
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are type I interferons (IFNs), including a single IFN-β and multiple subtypes of the IFN-
α family(16), that are secreted and activate target cells in autocrine and paracrine 
manners, conferring antiviral activity to the host, by inducing apoptosis in virus-infected 
cells, and rendering cells resistant to the infection (17-19). Furthermore, IFN and other 
cytokines critically contribute to the successful activation of the adaptive immunity, and 
the stimulation of hematopoietic stem cell turnover and proliferation (20). 
 The immune responses mediated by IFNs are regulated by two signaling 
cascades: a primary IFN producing signal induced by pathogens and a secondary signal 
mediated by IFN receptors (21,22). The genes encoding IFNs are regulated by the 
coordinate and cooperative assembly of an enhanceosome containing several 
transcription factors including activating transcription factor (ATF)/c-jun, NF-κB, and 
IFN regulatory factors (IRFs), which are activated by virus-induced signaling (23-26). 
The IFNs expressed in response to viral infections relay a secondary signal through 
interaction with the IFN receptors (IFNRs) on the cell surface and induce the expression 
of hundreds of IFN-inducible genes, such as genes encoding dsRNA-dependent protein 
kinase R (PKR), 2'-5'-oligoadenylate synthetase (OAS), RNA-specific adenosine 
deaminase ADAR1 (adenosine deaminase acting on RNA-1), and RNA-editing enzyme 
APOBEC3G (27). PKR phosphorylates the translation initiation factor elF2α, leading to 
the down regulation of mRNA translation (28). The 2'-5' OAS activates ribonuclease 
RNase L, promoting viral RNA degradation and stimulating antiviral responses (29,30). 
ADAR-1 and APOBEC3G deaminate viral RNA, leading to mutations of the viral 
genome (31). Together, these IFN-inducible proteins down-regulate protein synthesis, 
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promote cell growth arrest and induce apoptosis, thus creating an “antiviral state” to 
contain the spread of viruses (18). Furthermore, type I IFNs enhance the maturation of 
DCs and activate NK cells as well as macrophages. IFNs also stimulate antibody 
production by B cells and trigger the expansion and differentiation of cytotoxic T cells, 
facilitating the adaptive immune responses (32-34). 
 
Viral nucleic acids as common PAMPs recognized by PRRs during viral infections 
Viruses contain genetic material composed of either DNA or RNA that encodes 
viral structural components as well as synthetic and replication enzymes. Besides surface 
glycoproteins, these viral nucleic acids are commonly recognized as PAMPs by the 
innate immune system because of their specific structures that differ from the host DNA 
or RNA. For example, most viral DNA genomes contain unmethylated cytosine-guanine 
(CpG) dinucleotide sequences at a high frequency, while mammalian DNA has a low 
frequency of CpG dinucleotides and most are methylated. In addition, most viruses 
produce unique dsRNA, and some viruses produce uracil-rich ssRNA during portions of 
their life cycle. 
Several proteins that are involved in the recognition of viral nucleotides have 
been discovered, including the TLR family members TLR3, TLR7/8, and TLR9 
described above. TLR3 detects viral dsRNA and triggers TRIF-mediated pathways, 
leading to IRF-3 and NF-κB activation and IFN-β induction (35). Viral ssRNA and DNA 
are recognized by TLR7/8 and TLR9, respectively, and stimulate MyD88-mediated 
pathways, resulting in IRF-7 activation and IFN-α induction (36). 
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Because the TLRs are membrane-bound proteins, they can only recognize 
extracellular dsRNA or ssRNA associated with viral particles that are internalized into 
the endosomes by endocytosis. Nevertheless, in most types of cells the accumulation of 
intracellular dsRNA resulting from the replication of viruses also triggers host response 
mechanisms including the expression of type I IFN, through a TLR3-independent 
pathway (37). Later, three DExD/H box RNA helicases were identified as a family of 
cytosolic receptors sensing intracellular dsRNA. The prototypical member retinoic acid-
inducible gene-I (RIG-I), together with melanoma differentiation-associated gene 5 
(MDA5; also called Helicard) and laboratory of genetics and physiology 2 (LGP2), were 
named as RIG-I like receptors (RLRs). The RLR family becomes the central of research 
in these few years, as it is essential in the recognition of cytosolic viral RNA and the 
induction of type I IFNs and other pro-inflammatory cytokines such as interleukin-6 (IL-
6), conferring antiviral activity to the host cells and activating the adaptive immune 
responses. 
Given the critical roles of type I IFNs in innate immunity against viruses, the 
detection of viruses and the stimulation of IFNs secretion by RLRs and TLRs are very 
important for the antiviral innate immune responses (18,38). 
 
RIG-I and MDA5: virus sensing and signaling 
RNA viruses comprise approximately 80% of all viruses and in humans are 
etiologic agents of infectious diseases causing major public health concerns (39). RLRs 
and some TLRs are involved in the recognition of viral RNA. Whereas TLRs detect viral 
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components in specific cell types, such as macrophages and DCs, RLRs sense the 
infected viruses in the cytoplasm of most cell types except plasmacytoid DCs (pDCs) 
(40). In contrast to the TLRs described above, RLRs lack repetitive receptor elements 
such as LRRs which could serve as a recognition platform. Therefore, the finding that 
RLRs were involved in viral sensing in the cytosol was unexpected (41). 
The RLRs are DExD/H-box RNA helicases containing DECH motif and belong 
to the helicase superfamily 2 (SF2). The DExD/H box RNA helicases, defined by their 
ability to unwind dsRNA with their intrinsic ATPase activity, are found in almost all 
organisms from viruses to mammals and are involved in a wide variety of biological 
functions such as transcription, translation, pre-mRNA splicing, and RNAi (42-44). 
RIG-I was first isolated as a gene induced by retinoic acid in a promyelocytic 
leukemia cell line (45). It was then identified as a cDNA clone that activates IRF-
regulated reporter gene expression in response to transfection of the synthetic dsRNA 
analogue polyinosinic-polycytidylic acid (poly I:C) (41). Depletion of RIG-I inhibits 
IFN-β production in response to Newcastle disease virus (NDV), suggesting that RIG-I 
is required for virus-triggered signaling. 
MDA5, as the closest relative of RIG-I, was originally identified in human 
melanoma cells as a gene activated by IFN-β and protein kinase C-activating compound 
mezerein (46). MDA5 was then linked to the mediation of antiviral responses and 
identified as a binding target for V proteins of paramyxoviruses (47,48). 
Both RIG-I and MDA5 consist of two tandem CARDs at the N-terminus, a 
centrally located DExD/H-box RNA helicase domain with ATPase activity, and a C-
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terminal repressor or regulatory domain (CTD, or RD) (Figure 1.1) (49,50). RIG-I and 
MDA5 share 23% and 44% amino acid identities in the N-terminal tandem CARDs and 
the helicase domain, respectively. The CARDs of RIG-I and MDA5 participate in the 
signaling cascade. Overexpression of the CARDs alone is sufficient to induce antiviral 
signaling resulting in IFN production.  The CTDs and the helicase domains are involved 
in viral RNA sensing and the regulation of RLR activation (49,51). The helicase domain 
retains catalytic activity to unwind dsRNA in an ATP hydrolysis-dependent manner. 
However, the unwinding activity may be reversibly correlated with the antiviral 
signaling activity (52). 
 
 
 
Figure 1.1 Domain structures of the RIG-I-like receptors. 
RIG-I and MDA5 are composed of two tandem CARDs at the N-terminus, a central 
DECH helicase domain, and a C-terminal domain. Lacking the N-terminal CARDs, 
LGP2 shows a homologous domain architecture with only a helicase domain and a CTD. 
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Studies of RIG-I and MDA5 knockout mice demonstrated the differential roles of 
these two receptors in the recognition of RNA viruses (53). RIG-I is essential for the 
induction of IFNs in response of a set of RNA viruses including the paramyxoviruses 
such as NDV and Sendai virus (SeV), influenza A virus, vesicular stomatitis virus 
(VSV), and Japanese encephalitis virus (JEV) (40). In contrast, MDA5 is critical for the 
detection of picornaviruses, such as encephalomyocarditis virus (EMCV), Mengo virus, 
and Theiler’s virus (54). Some viruses such as Dengue virus (DEN), West Nile virus and 
reovirus are recognized by both receptors redundantly (55). Since the induction of type I 
IFNs by various RNA viruses is completely abolished in cells lacking both RIG-I and 
MDA5, the RLRs are likely sole cytosolic sensors of RNA viruses regulating type I IFN 
induction (53). 
 
LGP2: a regulator of RIG-I and MDA5 signaling 
The third RLR family member LGP2 was originally cloned as a gene 
neighboring the Stat3 and Stat5 loci on mouse chromosome 11, which encodes a 
cytoplasmic protein of previously unknown function (56). Later it was found to be a 
homolog of RIG-I and MDA5, with 31% and 41% amino acid identities to the helicase 
domains of RIG-I and MDA5, respectively, but it completely lacks CARDs (Figure 1.1). 
Therefore it has no direct signaling capability and functions as a regulator of RIG-I and 
MDA5 signaling (57,58). LGP2 has low basal expression level at steady state, but is 
strongly inducible by antiviral stimulations such as poly I:C transfection, virus infection, 
and IFN-α treatment. LGP2 exhibits high affinity for both dsRNA and 5'-ppp ssRNA and 
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serves as a negative regulator of RIG-I signaling (57,59), either by sequestering dsRNA, 
inhibiting RIG-I conformational changes, or through a signaling pathway. On the other 
hand, LGP2 seems to enhance responses to poly I:C mediated by MDA5 (60). The 
controversial roles of LGP2 in antiviral signaling need to be explained in future studies.  
 
RNA ligands of RLRs 
Being innate immune receptors, the RLRs are able to discriminate between the 
self (host) and non-self (viral) RNAs. In addition, RIG-I and MDA5 respond to distinct 
but overlapping sets of viruses, suggesting that they specifically recognize different 
forms of virus RNA. In order to elucidate the specific RNA recognition by each of the 
RLRs, extensive studies have been carried out and several types of RNA ligands have 
been identified. 
For example, 5'-ppp ssRNA is recognized exclusively by RIG-I. Two initial 
studies using RNA transcribed from DNA templates by T7 RNA polymerase 
demonstrated that RNA containing 5'-ppp groups potently triggers the activation of RIG-
I upon transfection into various types of cells, and it was suggested that 5'-ppp ssRNA is 
the primary ligand of RIG-I (61,62). While the genomes of most RNA viruses contain 5'-
ppp RNA, the 5'-ppp moieties of most host RNA are either masked by a 7-methyl-
guanosine cap (in the case of mRNA) or removed during RNA processing (tRNA and 
rRNA) (63). Therefore the self RNA can avoid triggering the RLRs signaling cascade. 
However, recent research has revealed that 5'-ppp per se may not be sufficient 
for RIG-I activation and a dsRNA structure may be required. Studies using chemically 
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synthesized dsRNA or hairpin RNA containing 5'-ppp demonstrated that dsRNA with 5'-
ppp is a strong activator of RIG-I and the base-pairing near the 5'-ppp is necessary 
(64,65). On the other hand, other studies showed that dsRNA without 5'-ppp can also 
activate RIG-I signaling in transfected cells (66). In addition, the panhandle structure of 
the influenza virus genome was also recently reported as a RIG-I ligand (67). Because 
different forms of RNA, cell lines, and assays were used in these studies, questions 
remain about the exact structural features of viral RNA recognized by RIG-I.  
The synthetic dsRNA poly I:C was known as a potent non-viral IFN inducer and 
interacts with TLR3 (68). Poly I:C is generated by annealing poly I and poly C, and 
harbors a 5'-diphosphate (5'-pp) (69). Commercial poly I:C migrates as dsRNA of 4-8 kb 
in gel electrophoresis. Analysis of RIG-I and MDA5 knockout mice demonstrated that 
MDA5, but not RIG-I, is responsible for IFN induction in response to poly I:C 
(53,54,70). Interestingly, partial digestion of poly I:C with RNase III, which generates 
trimmed poly I:C of about 300 bp, transforms it from a ligand for MDA5 to a ligand for 
RIG-I, suggesting that MDA5 recognizes long dsRNA while RIG-I prefers short dsRNA 
(71). Consistent with this speculation, long dsRNA (> 2 kb) purified from EMCV 
infected cells can trigger MDA5-dependent IFN production. The reoviral genome 
consists of 10 segments with different sizes, including long (3.9 kb), medium (2.2-2.3 
kb), and short (1.2-1.4 kb). The long and short segments are ligands for MDA-5 and 
RIG-I, respectively (71). It is not clear how RIG-I and MDA5 discriminate between 
short and long dsRNA at the molecular level. 
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The structural basis of viral RNA recognition by RLRs 
Extensive protease treatment of the RIG-I/dsRNA complex followed by mass 
spectrometry and protein sequencing analysis identified that the CTD of RIG-I (residues 
792-925) is involved in dsRNA and 5'-ppp ssRNA recognition (52). The affinity of RIG-
I CTD for dsRNA or 5'-ppp ssRNA is slightly lower than that of full-length RIG-I, 
indicating that the helicase domain may also play some role in RNA binding (52,72). 
However, the helicase domain of RIG-I alone does not bind to RNA (52). 
To understand the structural basis of viral RNA recognition by RLRs, the 
structures of RIG-I, MDA5 and LGP2 CTDs have been determined by X-ray 
crystallography and nuclear magnetic resonance (NMR) (52,60,72,73). Although the 
amino acid sequence of RIG-I CTD is about 30% and 29% identical to the CTDs of 
MDA5 and LGP2 respectively (Figure 1.2), the structures of the three RLR CTDs are 
very similar and can be superimposed with only slight differences in the flexible loop 
regions (Figure 1.3). The CTD is a flat domain with a convex and a concave side and 
dimensions of about 45 Å × 35 Å × 30 Å. Four conserved cysteine residues coordinate a 
zinc atom which plays a crucial role in maintaining proper folding and functioning of the 
CTD. The structures revealed a highly conserved RNA binding cleft in the CTD of 
RLRs (49). NMR titrations of RIG-I CTD indicated that a large positively charged 
surface located at the center of the structure is involved in both 5'-ppp ssRNA and 
dsRNA recognition (52). Mutagenesis of several positively charged residues on this 
surface either reduced or disrupted RNA binding by RIG-I and LGP2 (52,60,72).  
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Figure 1.2 Sequence alignment of human RIG-I, MDA5, and LGP2 CTDs. 
Residues conserved in all three proteins are colored red. Conserved residues that are 
involved in dsRNA binding surface are highlighted in yellow. Conservatively replaced 
residues are in green and blue. 
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Figure 1.3 Comparison of CTD structures of RLRs. 
(A) Ribbon model of superimposed MDA5 and LGP2 CTDs. 
(B) Ribbon model of superimposed RIG-I and MDA5 CTDs. 
(C) Stereo view of superimposed α-Carbon of three RLR CTDs. 
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The crystal structure of LGP2 CTD bound to an 8-bp dsRNA, which was the first 
CTD/RNA complex structure, was later determined in our laboratory (74), revealing that 
LGP2 specifically recognizes the blunt ends of dsRNA. This provides the first insight 
into how the RLRs interact with dsRNA. The recognition of the terminal structures of 
viral RNA allows the receptors to discriminate signature structures of viral RNA and 
detect the level of infection by sensing the concentration of viral RNA as well. This 
mechanism of viral RNA sensing by the RLRs suggests a way to fine-tune the immune 
response to viral infection and avoid damage to the host cells. Consistent with findings 
from the LGP2/dsRNA complex structure, luciferase reporter gene assays showed that 
RIG-I was activated by short dsRNA with blunt ends but not by dsRNA with either 3'- or 
5'-overhangs (74). 
 
Mechanism of RLR activation, signaling, and regulation 
Overexpression of full-length RIG-I exhibits low levels of basal activity (58). 
Furthermore, although IFN treatment strongly induces RIG-I protein, IFN treatment 
alone does not activate IFN genes. Thus, an autorepression model has been proposed 
(Figure 1.4). Without RNA activation, full-length RIG-I is unable to induce downstream 
signaling, possibly due to intramolecular inhibition by the CTD, which mediates a closed 
structure (38,49). The engagement of viral RNA by RIG-I induces an ATP-dependent 
conformational change, exposing the CARDs for the recruitment of downstream adaptor 
protein interferon promoter stimulator 1 (IPS-1, also known as MAVS, VISA, or 
Cardif), which is located on the outer membrane of mitochondria and contains an N-
 17 
terminal CARD (75-78). Activated RIG-I interacts with IPS-1 through CARD-CARD 
interaction (38,51), serving as a platform for the assembly of signaling complexes 
involving TRAF3 and TRADD (38,79). TRAF3 leads to the activation of the 
noncanonical IκB (inhibitor of κB) kinase-ε (IKKε) and TANK-binding kinase-1 
(TBK1) (80) that activate IRF3 and IRF7 by phosphorylation (81,82). Activated IRF3 
and IRF7 translocate to the nucleus and bind to the IFN-stimulated response elements 
(ISREs), inducing the transcription of type I IFN genes (26,80,83). The TRADD and 
FADD arm of the signaling pathway are involved in the activation of transcription 
factors NF-κB and IRFs that regulate the expression of both pro-inflammatory cytokines 
and type I IFNs (84,85). In addition, post-translational modifications of RIG-I, including 
ubiquitination, phosphorylation, and SUMOylation, have been reported to be important 
for the activation or regulation of RIG-I signaling (86,87). Moreover, RIG-I dimerization 
or oligomerization is also likely to be critical for its function (88). 
The autoregulation by the CTD does not appear to be conserved in MDA5, since 
the expression of MDA5 in cells results in high basal signaling activity in the absence of 
RNA, although the addition of RNA ligand increases MDA5 signaling (89). 
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Figure 1.4 Model of RIG-I activation and signaling. 
RIG-I is expressed in cytoplasm as an inactive form, in which CARDs are masked 
sterically by intra-molecular interaction with CTD. After viral infection, viral RNA 
binds to RIG-I and induces a conformational change in the presence of ATP. CARDs are 
exposed and interact with a downstream adaptor, IPS-1 (also called MAVS, VISA and 
Cardif), on mitochondria. IPS-1 interacts with various adaptor molecules leading to the 
activation of regulatory kinases, TBK1, IKKi (ε), and the IKKα/β/γ complex. These 
kinases activate respective transcription factors, IRF-3, IRF-7, and NF-κB, which 
participate in the activation of IFN and other cytokine genes. 
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Overview of dissertation chapters 
Our general interest is to investigate the structural basis of the interactions 
between RLR receptors and their RNA ligands, and the activation of RLR antiviral 
signaling. With Chapter I as an introduction to the innate immune receptors RLRs, in the 
following chapters the structural and biochemical studies of two RLR proteins, RIG-I 
and MDA5, are described. This dissertation is primarily focused on the prototypical 
RLR protein RIG-I in Chapters II, III, and V, with an additional study performed on 
MDA5 in Chapter IV. 
Chapter II and III are focused on the interactions between RIG-I CTD and 
various RNA ligands. Examinations of the RNA ligand specificities and binding 
properties of RIG-I have been performed by extensive biochemical methods. High 
resolution crystal structures of RIG-I CTD bound to dsRNA with 5'-ppp group are 
described in Chapter II, while the crystal structure of RIG-I CTD bound to non-ppp 
dsRNA is described in Chapter III. The structural studies together with mutagenesis 
studies elucidate the detailed interactions between RIG-I CTD and different RNA 
ligands, and a comparison of them is discussed as well.  
Chapter IV describes the RNA binding properties of MDA5. Residues of MDA5 
CTD that are involved in dsRNA binding were mapped by an NMR titration study, 
showing a similar but also distinctive RNA-binding surface compared to RIG-I CTD. 
This enables the comparison of different binding interactions between RLRs and RNA 
ligands.  
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Chapter V discusses the cloning, protein overexpression, purification, 
crystallization trials, and preliminary X-ray diffraction data of a longer version of RIG-I 
consisting of its helicase domain and the CTD. This would provide insights into the role 
of RIG-I helicase domain plays in RNA detection and RIG-I activation for signaling.  
Chapter VI is the final chapter providing a brief summary on the research in this 
dissertation as well as the future directions that can still be pursued. 
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CHAPTER II 
STRUCTURAL BASIS OF 5'-TRIPHOSPHATE DOUBLE-STRANDED RNA 
RECOGNITION BY RIG-I C-TERMINAL DOMAIN*  
 
Background 
RIG-I is an innate immune receptor which detects viral RNA from replicating 
viruses in the cytoplasm and induces the secretion of type I IFNs (IFN-α and –β) and 
other pro-inflammatory cytokines, conferring antiviral activity to the host cells and 
activating acquired immune responses (18,19,34,38). RIG-I is responsible for sensing 
NDV, SeV, influenza A virus, VSV, and JEV, etc. (40). However, the types of RNA 
ligands that are specifically recognized by RIG-I are still under debate, and the 
mechanism of viral RNA recognition is not fully understood. 
The 5'-ppp group was initially identified as a key structural feature of viral RNA 
that was sensed by RIG-I, and it was suggested that 5'-ppp ssRNA is the primary ligand 
of RIG-I (61,62,90). However, recent studies demonstrated that dsRNA with 5'-ppp are 
potent activators of RIG-I (64,65). In addition, the crystal structure of human LGP2 
CTD bound to dsRNA showed that the termini of dsRNA are recognized by LGP2 (74).  
 
 
 
____________ 
*Reproduced with permission from “The structural basis of 5' triphosphate double-
stranded RNA recognition by RIG-I C-terminal domain” by Lu C., Xu H., Ranjith-
Kumar C.T., Brooks M.T., Hou T.Y., Hu F., Herr A.B., Strong R.K., Kao C.C., and Li P. 
2010. Structure. 18, 1032-1043. Copyright (2010) by Elsevier. 
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Similarly, blunt-ended dsRNA rather than dsRNA with 5'- or 3'-overhangs binds and 
stimulates the activation of RIG-I (66). Although blunt-ended dsRNA with 5'-ppp 
potently stimulates the activation of RIG-I, 5'-ppp dsRNA with 5'-overhangs does not 
stimulate the activation of RIG-I effectively (64). Because different forms of RNA, cell 
lines, and assays were used in these studies, questions remain about the structural 
features of viral RNA recognized by RIG-I.  
Limited proteolysis of RIG-I bound to dsRNA revealed that its CTD (residues 
792-925) is responsible for RNA binding (52). Structures of the CTDs of RIG-I, LGP2, 
and MDA5 have been determined recently, revealing a novel and conserved RNA-
binding domain structure (52,60,72,73). The structure of LGP2 CTD bound to dsRNA 
showed that the RNA binding surface is located on a positively charged surface (74). 
NMR titrations of RIG-I CTD showed that a similar binding surface is involved in RNA 
binding by RIG-I (52). Mutagenesis of several positively charged residues on this 
surface disrupted RNA binding and signaling by RIG-I (52,72). On the basis of the 
results from these studies, the ppp-binding site of RIG-I was predicted to be located at a 
large positively charged surface around residues Lys858 and Lys861 (52,72). However, 
how RIG-I recognizes the 5'-ppp of viral RNA remains to be established. 
To elucidate the structural basis of 5'-ppp dsRNA recognition by RIG-I, we 
expressed the CTD of human RIG-I, conducted extensive binding studies using RNA 
with different structures, and determined the crystal structures of RIG-I CTD bound to a 
14-bp GC-rich and a 12-bp AU-rich dsRNA. The structures revealed that RIG-I CTD 
recognizes the termini of dsRNA and interacts with the 5'-ppp through extensive 
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electrostatic interactions. Mutagenesis of key residues at the binding surface affected 
RNA binding and signaling by RIG-I. 
 
Materials and methods 
Construction of RIG-I CTD expression plasmids by molecular cloning 
The cDNA of human RIG-I (DDX58) was purchased from Open Biosystems 
(Thermo Scientific). The region encoding RIG-I CTD (residues 802-925) was cloned 
into bacterial expression vector pET22b(+) (Novagen) between NdeI and XhoI 
restriction sites, in order to be expressed with an C-terminal 6×His-tag. Residue Cys829 
was mutated to serine to prevent dimerization of the protein. RIG-I CTD was also cloned 
into bacterial expression vector pGEX (GE Healthcare) between NdeI and SalI 
restriction sites, to be expressed with an N-terminal GST-tag. 
The target genes were amplified by polymerase chain reaction (PCR) using a 
Platinum Pfx DNA Polymerase kit (Invitrogen) according to standard protocols. PCR 
products were confirmed by agarose gel electrophoresis and purified using a QIAquick 
PCR purification kit (QIAGEN). DNA primers (Integrated DNA Technologies, IDT) 
used in this study were: 
For pET22b(+) 
Forward primer 5'- TATATATACATATGGATAAGGAAAATAAAAAACTGCTC -3'  
Reverse primer 5'- TATATACTCGAGTTTGGACATTTCTGCTGG -3' 
For pGEX 
Forward primer 5'- TATATATACATATGGATAAGGAAAATAAAAAACTG -3' 
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Reverse primer 5'- TATATAGTCGACTCATTTGGACATTTCTGCTGG -3' 
PCR products and vectors were double-digested using restriction endonucleases 
and corresponding buffers (New England BioLabs Inc., NEB) as recommended by the 
manufacturer. Digested products were purified from agarose gels using a QIAquick Gel 
Extraction kit (QIAGEN). For ligation, a three- to ten-fold excess of the digested insert 
was incubated with linearized vector and T4 DNA ligase (Invitrogen), in a 10-μl reaction 
according to the manufacturer’s instructions. Ligation products were transformed into 
Escherichia coli (E. coli) DH5α cells which were selected on Luria Broth (LB) agar 
plates containing 100 μg/ml ampicilin. Plasmid DNA was isolated using a QIAprep Spin 
Miniprep kit (QIAGEN). All plasmid constructs have been confirmed by plasmid DNA 
sequencing (Institute of plant genomics and biotechnology, Texas A&M University).  
 
Site-directed mutagenesis 
For native RIG-I CTD construct, residue Cys829 was mutated to serine to 
prevent dimerization of the protein. For dsRNA binding surface analysis, 11 residues 
were mutated for binding studies. Point mutations were introduced by PCR using a 
QuikChange Site-Directed Mutagenesis kit (Stratagene). DNA primers (IDT) used in 
this study were: 
For C829S (used as native RIG-I CTD) 
Forward primer 5'- GAGTGATAGAGGAATGCCATTACACTGTGCTTGG -3'  
Reverse primer 5'- CCAAGCACAGTGTAATGGCATTCCTCTATCACTC -3' 
For H830A 
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Forward primer  
5'- TAAGAGTGATAGAGGAATCCGCTTACACTGTGCTTGGAGATG -3'  
Reverse primer  
5'- CATCTCCAAGCACAGTGTAAGCGGATTCCTCTATCACTCTTA -3' 
For H847E 
Forward primer  
5'- AGGAATGCTTTGTGAGTAGACCAGAGCCCAAGCCAAAGC -3'  
Reverse primer 5'- GCTTTGGCTTGGGCTCTGGTCTACTCACAAAGCATTCCT -3' 
For K849E 
Forward primer 5'- TGAGTAGACCACATCCCGAGCCAAAGCAGTTTTCA -3'  
Reverse primer 5'- TGAAAACTGCTTTGGCTCGGGATGTGGTCTACTCA -3' 
For K851E 
Forward primer 5'- AGTAGACCACATCCCAAGCCAGAGCAGTTTTCAAG -3'  
Reverse primer 5'- CTTGAAAACTGCTCTGGCTTGGGATGTGGTCTACT -3' 
For F853S 
Forward primer  
5'- CCACATCCCAAGCCAAAGCAGAGTTCAAGTTTTGAAAAAAGAGCA -3'  
Reverse primer  
5'- TGCTCTTTTTTCAAAACTTGAACTCTGCTTTGGCTTGGGATGTGG -3' 
For K858E 
Forward primer  
5'- CCAAAGCAGTTTTCAAGTTTTGAAGAGAGAGCAAAGATATTCTGTG -3'  
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Reverse primer  
5'- CACAGAATATCTTTGCTCTCTCTTCAAAACTTGAAAACTGCTTTGG -3' 
For K861E 
Forward primer  
5'- CAGTTTTCAAGTTTTGAAAAAAGAGCAGAGATATTCTGTGCCCG -3'  
Reverse primer  
5'- CGGGCACAGAATATCTCTGCTCTTTTTTCAAAACTTGAAAACTG -3' 
For D872A 
Forward primer 5'- CAGAACTGCAGCCATGCCTGGGGAATCCATGTG -3'  
Reverse primer 5'- CACATGGATTCCCCAGGCATGGCTGCAGTTCTG -3' 
For K907E 
Forward primer 5'- TTCAGACGCTGTACTCGGAGTGGAAGGACTTTCAT -3'  
Reverse primer 5'- ATGAAAGTCCTTCCACTCCGAGTACAGCGTCTGAA -3' 
For K909E 
Forward primer 5'- CGCTGTACTCGAAGTGGGAGGACTTTCATTTTGAG -3'  
Reverse primer 5'- CTCAAAATGAAAGTCCTCCCACTTCGAGTACAGCG -3' 
 Sequences of the mutants were confirmed by plasmid DNA sequencing (Institute 
of plant genomics and biotechnology, Texas A&M University). 
 
RIG-I CTD expression and purification 
For the overexpression of recombinant native RIG-I CTD and various mutants in 
E. coli system, competent BL21(DE3) cells were transformed with plasmid DNA 
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carrying the gene of interest. Cells were grown at 37°C in LB medium in the presence of 
antibiotics (100 μg/ml ampicilin) to an OD600 of 0.6-0.8. 0.2 mM of ZnSO4 was added to 
the medium because RIG-I CTD is a Zinc binding protein. Protein expression was 
induced by the addition of Isopropyl-β-D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 0.5 mM. After further growth overnight at 15°C, cells were harvested 
by centrifugation at 4°C, 6000 rpm for 10 min. 
For purification, cell pellets were resuspended in pre-chilled Tris-NaCl buffer 
(150 mM NaCl, and 20 mM Tris-HCl pH 7.5) and disrupted by sonication at 60% 
amplitude for 5 to 10 min, using a Sonic Dismembrator (Model 500, Fisher Scientific). 
Cell lysate was then centrifuged down at 4°C, 8000 rpm for 15 min. Supernatant was 
further centrifuged at 4°C, 16000 rpm for 20 min to completely remove the cell debris.  
The 6×His-tagged fusion proteins were first purified by nickel affinity 
chromatography on a His-Select nickel affinity resin (Sigma-Aldrich) column. After 
loading of soluble extracts, the resin was washed with Washing Buffer (500 mM NaCl, 
20 mM Tris-HCl pH 7.5, and 10 mM imidazole) to remove nonspecific proteins, prior to 
elution with Elution Buffer (150 mM NaCl, 20 mM Tris-HCl pH 7.5, and 250 mM 
imidazole). The purified mutants of RIG-I CTD were directly used for binding studies. 
For crystallization purpose, native RIG-I CTD was further purified by gel filtration 
chromatography on a Superdex75 (1.6 × 60) column (GE Healthcare) eluted with the 
Tris-NaCl buffer. The purity of the proteins was analyzed by sodium dodecyl sulfate 
(SDS) polyacrylamide gel electrophoresis (PAGE) on an 18% gel, which was stained 
with Coomassie Brilliant blue R-250. 
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The GST-tagged RIG-I CTD was purified by a Glutathione Sepharose 4 Fast 
Flow (GE Healthcare) column. After loading of soluble extracts, the column was washed 
with PBS buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4, 
pH 7.3). The bound protein was eluted by 10 mM reduced glutathione (GSH), and 50 
mM Tris-HCl pH 8.0. 
 
Preparation of RNAs used in binding studies and crystallization 
Different forms of RNA used in the binding studies and crystallizations are listed 
in Table 2.1. The non-ppp RNA oligomers were generated by chemical synthesis (IDT). 
The 5'-ppp RNA were transcribed in vitro from DNA template (IDT) using T7 RNA 
polymerase (expressed and purified from bacterial system in lab).  
The transcription reactions were carried out at 37˚C for 3 h, in a reaction mixture 
containing 40 mM Tris-HCl pH 8.0, 20 mM MgCl2, 2 mM spermidine, 10 mM 
dithiothreitol (DTT), 4.8 mM rNTP mix (1.2 mM each), 1 U/ml inorganic 
pyrophosphatase (IPP), 2 μM dsDNA template, and 0.15 mg/ml T7 RNA polymerase. 
The transcription products were purified by gel filtration chromatography on a 
Superdex75 (1.6 × 60) column (GE Healthcare) eluted with the Tris-NaCl buffer, and 
analyzed by urea-based denaturing PAGE. Each of the purified 5'-ppp RNA showed a 
single band with the expected length on the denaturing gels.  
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Table 2.1 Sequences of RNA used in this study. 
The 5'-ppp RNA were synthesized by in vitro transcription and purified by gel filtration 
chromatography or denaturing PAGE. The blunt-ended dsRNA were chemically 
synthesized by IDT.  
 
14-bp GC-rich 5'-ppp 
dsRNA 
5' pppGGCGCGCGCGCGCC 3' 
   3' CCGCGCGCGCGCGGppp 5' 
12-bp AU-rich 5'-ppp 
dsRNA 
5' pppAUAUAUAUAUAU 3' 
   3' UAUAUAUAUAUAppp 5' 
14-bp blunt-ended dsRNA 
without 5'-ppp 
5' GGCGCGCGCGCGCC 3' 
3' CCGCGCGCGCGCGG 5' 
13-nt 5'-ppp ssRNA 5' pppGGCGCAUAGGCCG 3' 
  
12-bp 5'-ppp dsRNA with 5'-
overhangs 
5' pppAUAUGCGCGCGCGCGC 3' 
       3' CGCGCGCGCGCGUAUAppp 5' 
12-bp 5'-ppp dsRNA with 3'-
overhangs 
 5' pppGCGCGCGCGCGCAUAU 3' 
3' UAUACGCGCGCGCGCGppp 5' 
24-bp 5'-ppp dsRNA 5' pppGGCGCGCGAGUCGACUCGCGCGCC 3' 
   3' CCGCGCGCUCAGCUGAGCGCGCGGppp 5' 
27-nt 5'-ppp ssRNA 5' pppGGUGCAGAUGAACUUCAGGGUCAGCUU 3' 
 
27-bp blunt-ended dsRNA 
without 5'-ppp 
5' AAGCUGACCCUGAAGUUCAUCUGCACC 3' 
3' UUCGACUGGGACUUCAAGUAGACGUGG 5' 
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All the dsRNA used were generated by annealing a ssRNA with palindromic 
sequence or two ssRNA strands with complementary sequences. The samples were 
annealed by heating the ssRNA at 95°C for 5 min and cooling gradually to room 
temperature. 
 
RNA binding studies by gel filtration chromatography 
In the binding studies of RIG-I CTD with different forms of RNA by gel 
filtration chromatography, each of the RNA samples (at about 100 μM) was mixed with 
equal volume of RIG-I CTD (at about 200μM), and 100 μl of samples were injected over 
a Superdex200 (10/300 GL) column (GE Healthcare) eluted with the Tris-NaCl buffer. 
The column was calibrated with a set of protein standards of different sizes (Bio-Rad) to 
allow the estimation of the sizes of the protein and RNA complexes. 
Binding studies for the mutants with the three different forms of RNA were 
carried out in the same way, but with final concentrations of about 36:12 μM 
(protein:RNA). 
 
RNA binding studies by electrophoretic mobility shift assay (EMSA) 
In the binding studies by EMSA, each type of RNA was mixed with excess RIG-
I CTD or mutants at a molar ratio of 1:3 at final concentrations of about 1.6:5 μM. The 
mixtures were resolved on 12% native polyacrylamide gels in Tris-boric acid buffer (89 
mM Tris, 89 mM boric acid) without EDTA. The gels were stained with ethidium 
bromide (EtBr) and visualized using a Gel Dox XR (Bio-Rad) system. 
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Analytical ultracentrifugation (AUC) 
To determine the stoichiometry of RIG-I CTD binding to the 14-bp 5'-ppp 
dsRNA, purified RIG-I CTD complex with 14-bp dsRNA was analyzed by AUC. The 
experiments were carried out by our collaborators at the University of Cincinnati (Dr. 
Andrew B. Herr group, Department of Molecular Genetics, Biochemistry, and 
Microbiology). 
For sedimentation velocity experiments, 400 μl of samples in Tris-NaCl buffer 
with 10 mM β-mercaptoethanol were centrifuged overnight at 48000 rpm at 10 °C in a 
Beckman XL-I using absorbance optics at 304 nm. The data were analyzed by the 
program Sedfit using the c(s) and c(M) models to determine differential sedimentation 
coefficient and apparent mass distributions, respectively. The complex sedimented as a 
single peak, with a sedimentation coefficient of 2.72 S and an estimated molecular mass 
of 38 kDa, similar to that expected for a 2:1 (protein:RNA) complex (38.5 kDa).  
To confirm the stoichiometry, the complex was also analyzed in a sedimentation 
equilibrium experiment. Briefly, 100 μl of samples of the complex at concentrations of 
15, 50, and 150 μM were spun at 19000, 22500, and 33000 rpm at 10°C until 
equilibrium was reached, and were scanned at 295 and 306 nm. The data were trimmed 
using WinReedit and globally analyzed using WinNonlin. The global analysis of nine 
data sets revealed that the data could be described by a single species with a reduced 
buoyant molecular weight of 1.883 (at a speed of 19000 rpm). To convert to 
experimental molecular weight, the partial specific volume must be known; for a protein 
and RNA complex this value corresponds to the weight average of each component in 
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the sedimenting species. The partial specific volume for RIG-I CTD alone was 
calculated to be 0.7258 ml/g at 10°C using Sednterp. The partial specific volume for the 
14-bp dsRNA was calculated to be 0.5688 ml/g using the NucProt Calculator server 
(http://www.molmovdb.org/cgi-bin/psv.cgi) and corrected to 10°C in Sednterp. Both 2:1 
and 2:2 complexes were considered, with weight-average partial specific volumes of 
0.6956 or 0.6716 ml/g, respectively. The molecular weight values calculated from the 
reduced buoyant molecular weight and appropriate partial specific volumes were only 
self-consistent in the case of a 2:1 complex, yielding an experimental molecular weight 
of 37339 Da (95% confidence interval, 33882 – 40796 Da). 
 
RNA binding studies by surface plasmon resonance (SPR) 
SPR experiments were carried out by our collaborators at the Fred Hutchinson 
Cancer Research Center in Seattle (Dr. Roland K. Strong group, Division of Basic 
Sciences). 
Binding interactions between RIG-I CTD and three different forms of RNA were 
analyzed by SPR at 25°C in HBS-EP+ buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 
mM EDTA, and 0.05% v/v P-20 surfactant) on a Biacore T100 system (Biacore AB, GE 
Healthcare). The goat anti-GST monoclonal antibody (mAb) (Biacore AB) at 30 μg/ml 
in 10 mM sodium acetate (pH 5.0) was immobilized on a CM5 sensor chip (Biacore AB) 
by standard amine coupling chemistry. Immobilization of 13000 response units (RU) of 
the antibody resulted in optimal responses in subsequent analyses. GST fusion protein of 
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RIG-I CTD (at 5 μg/ml) was captured over the immobilized anti-GST mAb surface at a 
flow rate of 10 μl/min for 120 seconds to reach 1200 RU response.  
For equilibrium binding studies, dilution series of different forms of RNA were 
injected in randomized duplicate runs at flow rates of 30, 50, and 50 μl/min for 10, 7, 
and 5 min for the 14-bp 5'-ppp dsRNA, the 14-bp blunt-ended dsRNA, and the 13-nt 5'-
ppp ssRNA, respectively, followed by a 5-min dissociation phase. Concentrations for the 
three forms of RNA in the dilution series were 0.08-10 nM, 0.6-80 nM, and 2.5-160 nM, 
respectively. 
To study the kinetics of RNA binding by RIG-I CTD, dilution series of the three 
different forms of RNA were injected in randomized duplicate runs at a flow rate of 50 
μl/min for 5 or 7 min, followed by a 3 or 4 min dissociation phase. Concentrations for 
the three forms of RNA in the dilution series were 0.3-5 nM, 0.6-10 nM, and 2.5-40 nM, 
respectively. Optimal regeneration of the sensor chip was achieved by injection of 10 
mM glycine (pH 2.2) at a flow rate of 20 μl/min for 210 seconds followed by HBS-EP+ 
buffer stabilization for 5 min. Sensorgrams obtained from the SPR measurements were 
analyzed by the double-subtraction method described by Myszka (91). The signal from 
the reference flow cell was subtracted from the analyte binding response obtained from 
the flow cell with captured ligand. Buffer reference responses were then averaged from 
multiple injections. The averaged buffer reference response was then subtracted from 
analyte binding responses, and the final double-referenced data were analyzed with 
BIAevaluation 3.0 software (GE Healthcare). For the equilibrium binding data, steady-
state binding levels of the analytes were plotted against analyte concentration, from 
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which the equilibrium binding constant was estimated. For the kinetic binding data, a 
one to one binding model was used to globally fit the data to derive the association and 
dissociation rate constants. 
 
IFN-β luciferase reporter gene assays 
IFN-β luciferase reporter gene assays were used to analyze the activities of three 
different forms of RNA in stimulating RIG-I signaling in the human embryonic kidney 
(HEK) 293T cell line. These cell-based assays were performed by our collaborators at 
the Indiana University, Bloomington (Dr. C. Cheng Kao group, Department of 
Molecular and Cellular Biochemistry). The RNA used in the assays were purified either 
by preparative denaturing PAGE or by gel filtration chromatography. 
The luciferase assays used actively growing HEK 293T cells plated in CoStar 
White 96-well plates at 4.4 × 104 cells per well. When the cells were ~80% confluent, 
they were transfected with a mixture of Lipofectamine 2000 reagent (Invitrogen) and 
constant amounts of the luciferase reporter plasmid IFN-β luc (30 ng per transfection; 
gift from Dr. Rongtuan Lin, Lady Davis Institute for Medical Research, Montreal, QC, 
Canada), the Renilla luciferase control plasmid phRL-TK (5 ng; Promega), and human 
RIG-I plasmid pUNO-hRIG-I (0.5 ng; Invivogen). The cells were incubated for 24 h to 
allow expression from the plasmids. Three different forms of RNA at 5, 10 and 50 nM 
concentrations were then transfected into the cells to stimulate RIG-I dependent 
signaling. After 16 h incubation, the cells were analyzed using the Dual-Glo Luciferase 
Assay System reagents (Promega), quantifying luminescence with the BioTek Synergy2 
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Plate Reader. The ratios of firefly luciferase reporter over Renilla luciferase control were 
determined.  
Signaling of RIG-I mutants were analyzed under similar conditions. Mutations of 
full-length RIG-I were performed using pUNO-hRIG-I (Invivogen) as template. The 
cells were transfected with plasmid of RIG-I wild type or mutants along with IFN-β 
luciferase reporter and Renilla luciferase control plasmids, and stimulated with three 
forms of RNA at a final concentration of 50 nM. The firefly over Renilla luciferase ratio 
obtained with wild-type RIG-I induced with RNA was considered as 100% activity. 
Expression of wild-type and mutants of full-length RIG-I in the transfected cells were 
confirmed by western blot using anti-RIG-I antibody (C-15, sc-48929, Santa Cruz 
biotechnology).  
 
Purification and Crystallization of RIG-I CTD and dsRNA complexes 
Purified RIG-I CTD was mixed with the 14-bp or the 12-bp 5'-ppp dsRNA at a 
molar ratio of about 3:1 (excess protein), and the 2:1 (RIG-I CTD:dsRNA) complexes 
were purified by gel filtration chromatography on a Superdex75 (1.6 x 60) column (GE 
Healthcare) eluted with the Tris-NaCl buffer. After purification, 5 mM DTT was added 
to the complexes, and the samples were concentrated for crystallization. 
The complex of RIG-I CTD with the 14-bp GC-rich dsRNA was crystallized at 
about 15 mg/ml, in 18% polyethylene glycol (PEG) 3350, 0.2 M (NH4)2SO4, and 0.1 M 
Bis-Tris (pH 5.5) at 4°C. Large single crystals grew in about one week.  
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The complex of RIG-I CTD with the 12-bp AU-rich dsRNA was crystallized 
under similar conditions in 18% PEG 3350, 0.2 M (NH4)2SO4, and 0.1 M Bis-Tris (pH 
6.5). 
 
Data collection and structural determination 
For data collection, the crystals were transferred stepwise into a cryoprotectant 
containing 30% PEG 400 and were flash frozen in liquid nitrogen. Diffraction data were 
collected using a Rigaku RAXIS IV++ image plate detector mounted on a Rigaku 
Micromax-007HF generator. The diffraction data were processed with the HKL2000 
package (92). 
The complex of the 14-bp GC-rich dsRNA and RIG-I CTD crystallizes in 
orthorhombic space group P212121 with the following cell dimensions: a = 41.49 Å, b = 
96.87 Å, c = 103.40 Å. The crystallographic asymmetric unit (ASU) contains one 2:1 
(RIG-I CTD:dsRNA) complex. The 12-bp AU-rich dsRNA complex crystallizes in 
hexagonal space group P65 with cell dimensions as follows: a = b = 82.90 Å, c = 111.16 
Å, and γ = 120°. There is one 2:1 (RIG-I CTD:dsRNA) complex in the ASU. The crystal 
is hemihedrally twinned with a twin fraction of 0.478 with twinning operators h, -h-k, -l. 
The twining fraction was determined using CNS (93). 
Structures of the RIG-I CTD in complex with the 14-bp and 12-bp dsRNA were 
determined by molecular replacement using MOLREP in the CCP4 suite (94) using the 
crystal structure of RIG-I CTD in isolation as the search model (PDB code: 2QFB, chain 
A). The structural models were rebuilt using O. After several rounds of rebuilding and 
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refinement with CNS, electron density for the dsRNA became apparent. A 14-bp and a 
12-bp dsRNA were manually docked into the electron density map and rebuilt with O 
(95). The structures were refined by several rounds of positional, simulated annealing 
and individual B-factor refinement using CNS followed by extensive manual 
remodeling. The structure of RIG-I CTD bound to the 12-bp AU-rich dsRNA was 
refined in CNS against the twinned data. A total of 20357 reflections, which correspond 
to 86% of a complete dataset, were used in the structural refinement. Only 5.5% of the 
diffraction data (1309 reflections) were rejected due to twinning. Noncrystallographic 
symmetry (NCS) restraints were not applied during the refinement because of the 
different crystal packing environment of the RIG-I CTDs in the two complexes. 
The atomic coordinates and structure factors of RIG-I CTD bound to the 14-bp 
and the 12-bp 5'-ppp dsRNA have been deposited with the RCSB Protein Data Bank 
under the accession codes 3LRN and 3LRR. The structural figures were generated with 
PyMol (http:///www.pymol.org). 
 
Results 
RIG-I CTD interacts with various forms of RNA 
Understanding of RIG-I structure and function requires the elucidation of the 
chemical basis for viral RNA recognition by RIG-I. Since the CTD of RIG-I is 
responsible for viral RNA recognition, we have expressed and purified human RIG-I 
CTD and characterized its ligand binding properties with various forms of RNA, by gel 
filtration chromatography. 
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Figure 2.1 Bind studies of RIG-I CTD and RNA with or without 5'-ppp groups by gel 
filtration chromatography. 
(A) RIG-I CTD binds to a 14-bp GC-rich 5'-ppp dsRNA. RIG-I CTD is shown by the 
black chromatogram. The RNA is shown by the red chromatogram. The mixture of the 
protein and RNA is shown by green. Elution volumes of four protein standards are 
shown above the chromatograms. 
(B) RIG-I CTD binds to a 12-bp AU-rich 5'-ppp dsRNA. 
(C) RIG-I CTD binds to a 13-nt 5'-ppp ssRNA. 
(D) RIG-I CTD binds to a 14-bp GC-rich dsRNA without a 5'-ppp group. 
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Figure 2.2 Bind studies of RIG-I CTD and RNA by gel filtration chromatography. 
(A) RIG-I CTD binds to a 12-bp 5'-ppp dsRNA with 3'-overhangs (green). Treatment of 
the dsRNA with SAP reduced the binding between RIG-I CTD and the RNA (blue). 
Positions of the protein and the RNA alone are shown above the chromatograms. 
(B) RIG-I CTD binds to a 12-bp 5'-ppp dsRNA with 5'-overhangs (green). Treatment of 
the dsRNA with SAP reduced the binding between RIG-I CTD and the RNA (blue). 
(C) Treatment of a blunt-ended 12-bp 5'-ppp dsRNA (green) with SAP reduced its 
binding for RIG-I CTD (blue). 
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First, we tested the bindings of blunt-ended RNA with 5'-ppp groups. A 14-bp 
GC-rich dsRNA, a 12-bp AU-rich dsRNA and a 13-nt ssRNA were synthesized by in 
vitro transcription using T7 RNA polymerase (Table 2.1). We found that the 14-bp 
dsRNA with 5'-ppp binds to RIG-I CTD and forms a stable complex which is 
represented as a single peak eluted at higher molecular weight (Figure 2.1A). The 12-bp 
AU-rich dsRNA also binds to RIG-I CTD and forms a complex (Figure 2.1B), indicating 
that RIG-I has no preference for specific bases within the RNA. Surprisingly, the 13-nt 
ssRNA with 5'-ppp also binds to RIG-I CTD (Figure 2.1C).  In addition, we found a 
blunt-ended dsRNA with the same sequence as the 14-bp GC-rich 5'-ppp dsRNA but 
lacking the triphosphate group binds to RIG-I CTD as well (Figure 2.1D). 
Second, we tested whether the 5'- or 3'-end overhanging regions of 5'-ppp 
dsRNA affect RNA binding to RIG-I CTD. We found that 5'-ppp dsRNA with either 3'- 
or 5'-overhanging nucleotides retained binding to RIG-I CTD (Table 2.1, Figure 2.2A 
and B). However, treatment of these dsRNA with shrimp alkaline phosphatase (SAP) 
that removes the 5'-ppp groups dramatically reduced their binding with RIG-I CTD 
(Figure 2.2A and B), demonstrating that the 5'-ppp increases the affinity of the dsRNA 
for RIG-I. Consistent with this observation, treatment of the 12-bp 5'-ppp dsRNA 
without 3'- or 5'-overhangs using SAP also reduced its binding for RIG-I CTD (Figure 
2.2C). 
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The stoicheometry between RIG-I CTD and RNA ligands 
From the gel filtration chromatograms of RIG-I CTD binding study, the 
molecular weight of the protein and RNA complexes, and hence the stoicheometry 
between them, can be calculated by comparing the elution volumes of the complexes 
with those of the protein standards. The binding ratio of RIG-I CTD with dsRNA, with 
or without the 5'-ppp group, is estimated to be about 2:1, while that of RIG-I CTD with 
5'-ppp ssRNA is 1:1. 
To confirm the stoichiometry estimated from the gel filtration binding studies, 
sedimentation velocity and equilibrium analyses by AUC were performed with the help 
of our collaborators. The analyses of purified RIG-I CTD bound to the 14-bp GC-rich 5'-
ppp dsRNA yield an experimental molecular weight of about 38 kDa, which agrees with 
a 2:1 complex (RIG-I CTD:dsRNA; 38.5 kDa), demonstrating that the stoichiometry 
between the protein and the dsRNA is 2:1 (Figure 2.3). 
 
The RNA binding affinities of RIG-I CTD 
The affinity and kinetic properties of ligand binding to immunoreceptors 
determine the strength and duration of the signals initiated by these receptors. To 
determine the affinities and kinetic properties of RNA binding by RIG-I CTD, we 
expressed and purified GST-tagged RIG-I CTD and conducted RNA binding studies by 
SPR with the help of our collaborators.  
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Figure 2.3 Stoicheometry between RIG-I CTD and the 14-bp GC-rich 5'-ppp dsRNA 
determined by AUC. 
AUC analyses of a purified protein complex by sedimentation velocity (inset) and 
equilibrium. The experimental molecular weight values from velocity (about 38 kDa) 
and equilibrium (37339 Da) data were consistent only with the formation of a 2:1 
complex.  
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Figure 2.4 The binding affinities between RIG-I CTD and RNA determined by SPR. 
(A) Equilibrium binding study of RIG-I CTD with the 14-bp GC-rich 5'-ppp dsRNA. 
The dissociation constant (Kd) was derived by fitting of the equilibrium binding data to a 
one site binding model (lower panels). 
(B) Equilibrium binding study of RIG-I CTD with the 14-bp non-ppp dsRNA. 
(C) Equilibrium binding study of RIG-I CTD with a 13-nt 5'-ppp ssRNA. 
(D) Kinetic binding studies of RIG-I CTD with the 14-bp GC-rich 5'-ppp dsRNA. The 
association and dissociation rate constants (kon and koff) were derived from global fitting 
of the binding data to a 1:1 binding model (red curves). Half-life (t1/2) for each of the 
protein:RNA complex was calculated from the koff. The calculated dissociation constant 
(KD, calc) was derived by division of the dissociation rate constant (koff) by the association 
rate constant (kon). 
(E) Kinetic binding studies of RIG-I CTD with the 14-bp non-ppp dsRNA. 
(F) Kinetic binding studies of RIG-I CTD with the 13-nt 5'-ppp ssRNA.
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Figure 2.4 Continued. 
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Equilibrium binding studies showed that the affinity of RIG-I CTD for the 14-bp 
5'-ppp dsRNA is 0.32 ± 0.05 nM (Figure 2.4A). The affinity of RIG-I CTD for the 14-bp 
dsRNA without 5'-ppp is 4.6 ± 0.6 nM (Figure 2.4B), about 15 times lower than the 
affinity for the 5'-ppp dsRNA. The 13-nt 5'-ppp ssRNA binds to RIG-I CTD with an 
affinity of 7.6 ± 0.9 nM (Figure 2.4C). The calculated dissociation constants (KD, calc = 
koff / kon) derived from the kinetic binding studies are similar to those derived from the 
equilibrium binding studies (Figure 2.4). Although RIG-I CTD interacts with RNA 
primarily through electrostatic interactions, binding of the 14-bp 5'-ppp dsRNA by RIG-I 
CTD shows slow association rate and slow dissociation rate (Figure 2.4D), suggesting 
that a conformational change of the protein is likely needed for RNA binding. It is 
possible that other types of interactions, such as hydrogen bonding and hydrophobic 
interactions may also contribute to RNA binding. In contrast, the binding of blunt-ended 
dsRNA lacking a 5'-ppp shows faster association and dissociation rates (Figure 2.4E). 
Binding of the 13-nt 5'-ppp ssRNA shows kinetic properties similar to that of the 5'-ppp 
dsRNA (Figure 2.4F). These results indicate that the 5'-ppp plays an important role in 
determining the kinetic properties of RNA binding by RIG-I CTD. The higher affinity of 
the 5'-ppp dsRNA and the longer half-life (t1/2 = 327 ± 2 s) of its complex with RIG-I 
CTD suggest that dsRNA with 5'-ppp should be a more potent stimulator of RIG-I. 
 
RIG-I signaling activities stimulated by various forms of RNA in vivo 
The activities of three different forms of RNA in stimulating RIG-I signaling 
were examined by IFN-β luciferase reporter gene assays. HEK 293T cells were 
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transfected with plasmid of RIG-I along with IFN-β luciferase reporter and Renilla 
luciferase control plasmids, before stimulated with 5'-ppp ssRNA, 5'-ppp dsRNA, or 
dsRNA without 5'-ppp. These studies showed that the three forms of RNA are all 
capable of activating RIG-I-dependent reporter activities (Figure 2.5). The relative 
activities of 5'-ppp RNA are similar, whereas the non-ppp dsRNA is slightly less active. 
When used at the lowest concentration (5 nM), 5'-ppp dsRNA shows higher activity than 
non-ppp dsRNA or 5'-ppp ssRNA. 
 
 
 
 
 
 
Figure 2.5 The signaling activities of three different RNA ligands for RIG-I by IFN-β 
luciferase assays. 
The assays show the activities of a 27-nt 5'-ppp ssRNA (3PssR27), a 24-bp 5'-ppp 
dsRNA (3PdsR24), and a 27-bp dsRNA without 5'-ppp (dsR27) in stimulating RIG-I 
signaling in HEK 293T cells. The error bars correspond to the standard deviations of 
signals from three independent transfections.  
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Table 2.2 Data collection and refinement statistics of 5'-ppp dsRNA complex crystals. 
 
 RIG-I CTD : 14-bp dsRNA RIG-I CTD : 12-bp dsRNA 
Data Collection   
Space group P212121 P65 
Cell dimensions 
a, b, c (Å) 
α, β, γ  (°) 
 
41.49, 96.87, 103.40 
90.0, 90.0, 90.0 
 
82.90, 82.90, 111.16 
90.0, 90.0, 120.0 
Resolution (Å) 50-2.60 (2.69-2.60)a 50.00-2.15 (2.23-2.15)a 
Rsym (%) 8.6 (58.7) 7.1 (45.7) 
I/σI 27.4 (3.2) 36.0 (4.4) 
Completeness (%) 98.7 (96.3) 93.5 (90.4) 
Redundancy 4.5 (4.4) 6.5 (6.3) 
Refinement   
Resolution (Å) 50-2.60 50-2.15 
No. of reflections 12530 20357 
Rwork/Rfree (%) 22.1/28.5 18.7/22.7 
No. of atoms 
Protein 
RNA 
Ion 
Water 
 
1998 
620 
2 
54 
 
1998 
522 
2 
0 
B-factor 
Protein 
RNA 
Ligand/ion 
Water 
 
45.9 
69.5 
45.0 
49.0 
 
37.3 
70.7 
35.1 
N/A 
R.m.s. deviations 
Bond lengths (Å) 
Bond angles (°) 
 
0.013 
1.69 
 
0.009 
1.54 
a Diffraction data were collected using one single crystal for each structure. Values in the 
parentheses are for the highest-resolution shell. 
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Figure 2.6 Structures of RIG-I CTD bound to 5'-ppp dsRNA.  
(A) Crystal structure of RIG-I CTD bound to the 14-bp GC-rich 5'-ppp dsRNA (PDB 
code 3LRN). The nucleotides at the 5'-ends of the dsRNA containing the ppp are shown 
as space filling models. The zinc ions bound to RIG-I CTD are shown as gray spheres.  
(B) Structure of the RIG-I CTD bound to the 12-bp AU-rich 5'-ppp dsRNA (PDB code 
3LRR). The orientations of RIG-I CTD (Chain A) relative to the dsRNA are the same in 
the two structures. 
(C) Stereo representation of the σA weighted 2Fo - Fc map for the 5' three nucleotides in 
the 14-bp GC-rich 5'-ppp dsRNA complex structure. The first nucleotide 3pG1 contains 
a ppp group. RIG-I CTD is shown as cyan ribbons. The nucleotides are shown in ball-
and stick models. 
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Crystal structures of RIG-I CTD bound to 5'-ppp dsRNA 
To elucidate the structural basis of 5'-ppp dsRNA recognition by RIG-I, we 
cocrystallized RIG-I CTD (residues 803 to 923) with a 14-bp GC-rich dsRNA (with self-
complementary sequence of 5' pppGGCGCGCGCGCGCC 3') or a 12-bp AU-rich 
dsRNA (with self-complementary sequence of 5' pppAUAUAUAUAUAU 3'). The 
crystal structures of the complexes were determined by molecular replacement and 
refined at 2.60 Å and 2.15 Å resolutions, respectively. Crystals of the 12-bp AU-rich 
dsRNA complex are merohedrally twinned and the structure was refined against the 
twinned data using CNS (93). Statistics of data collection and structural refinement are 
listed in Table 2.2. 
The overall structures of the two crystals are shown in Figure 2.6. Consistent 
with the stoichiometry determined by AUC, the crystallographic ASUs for the two 
complex crystals contain a 2:1 complex between RIG-I CTD and the dsRNA (Figure 
2.6A and B). The complexes exhibit pseudo two-fold symmetry along the two-fold axis 
of the palindromic dsRNA. The orientations of the dsRNA relative to the RIG-I CTD in 
the two complexes are similar (Figure 2.6A and B). The 5'-ppp groups of the dsRNA are 
well defined at the four binding sites in the two complexes and interact with the protein 
in similar ways (Figure 2.6C). Structures of four RIG-I CTDs in the two complexes are 
similar; the root mean square deviations (r.m.s.d) between the Cα atoms of RIG-I CTD 
within each complex or between the two complexes are only 0.3 to 0.5 Å. Discussions of 
the complex structure below are based on the structure of RIG-I CTD (Chain A) in the 
14-bp GC-rich dsRNA complex because of the better-defined electron density map at 
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this interface (Figure 2.6C) and more complete diffraction data used in the structural 
refinement (Table 2.2).  
The overall structure of RIG-I CTD in the complex is similar to the structure of 
RIG-I CTD in isolation (r.m.s.d of about 0.7 Å). The largest structural difference 
between free and RNA bound RIG-I CTD occurs at the loop between strands β5 and β6 
(loop 5-6) from His847 to Ser855 (Figure 2.7). The average deviation for the Cα atoms 
of these eight residues is 1.67 Å in the two structures. As reflected in the nine structures 
of RIG-I CTD in the crystallographic ASU, this loop is highly flexible in the structures 
of RIG-I CTD in isolation (72). The structure of RIG-I CTD in solution also revealed 
that this loop is flexible (52). However, the four structures of the RIG-I CTD in the two 
complexes are highly similar, suggesting that dsRNA binding stabilizes the specific 
conformation of loop 5-6. 
 
RIG-I CTD recognizes the termini of 5'-ppp dsRNA 
As predicted from our previous structural studies of the LGP2 CTD: dsRNA 
complex (74), RIG-I CTD recognizes the termini of the 5'-ppp dsRNA (Figure 2.6). The 
dsRNA in the complex adopts a typical A-form double helical structure. The RNA-
binding surface of RIG-I CTD is located at a large saddle-shaped surface defined by the 
hairpin containing strands β3 and β4, the loop connecting strands β5 and β6, the β-sheet 
containing strands β5 to β8, the loop connecting strands β8 and β9, and the loop 
connecting strand β10 to the C-terminus (Figure 2.8).  
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Figure 2.7 The conserved structures of RLR CTDs. 
(A) Superposition of RIG-I CTD structures in isolation (yellow) and in complex with 5'-
ppp dsRNA (blue). 
(B) Superposition of RNA bound RIG-I CTD (blue) and LGP2 CTD (green) structures. 
(C) Superposition of structures of RNA bound RIG-I CTD (blue) and MDA5 CTD in 
isolation (orange). 
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Figure 2.8 Stereo close up view of the interface between RIG-I CTD and the terminus of 
the 14-bp 5'-ppp dsRNA. RIG-I CTD (Chain A) is shown as cyan ribbons and the 
dsRNA is shown as stick models. Key residues of RIG-I CTD involved in RNA binding 
are shown as stick models. 
 
 
 
Figure 2.9 Stereo close up view of the interactions between RIG-I CTD and the 5'-ppp 
group of the 14-bp GC-rich dsRNA. 
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Figure 2.10 Surface representation of RIG-I CTD bound to 5'-ppp dsRNA showing the 
shape and charge complementarity between RIG-I CTD and the terminus of the 5'-ppp 
dsRNA. Positively charged surfaces are colored blue and negatively charged surfaces are 
red. The orientation of RIG-I CTD relative to the dsRNA on the left panel is similar to 
the orientation of the protein in Figure 2.8. 
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RIG-I CTD interacts with the dsRNA primarily through extensive electrostatic 
interactions with the 5'-ppp and the phosphodiester backbone (Figure 2.8 and 2.9). The 
exposed base pairs at the termini of the dsRNA interact with RIG-I CTD through 
hydrophobic interactions (Figure 2.9). 
The RNA-binding surface of RIG-I CTD exhibits a high degree of shape and 
charge complementarity to the blunt-ends of 5'-ppp dsRNA (Figure 2.10). The total 
buried surface area at the RIG-CTD: dsRNA interface is approximately 1200 Å2, with 
primary contributions from the first four nucleotides at the 5'-end of the dsRNA (buried 
surface area of about 900 Å2). The last three nucleotides at the 3'-end of the 
complementary strand only make minor contributions to dsRNA binding (buried surface 
area of about 300 Å2). The average shape correlation statistics (Sc) is 0.62 for the four 
dsRNA-protein interfaces; the Sc value is a measure of the degree to which two 
contacting surfaces are geometrically matched, with an Sc value of 1.0 indicating a 
perfect fit (96). 
 
Structural basis of 5'-ppp dsRNA recognition by RIG-I CTD  
As predicted from previous mutagenesis studies (52,72), the 5'-ppp binding site 
of RIG-I CTD is located at a large patch of positively charged surface around residues 
Lys858 and Lys861. Four positively charged residues interact with the 5'-ppp through 
electrostatic interactions (Figure 2.8 and 2.9). Lys888 interacts with the α-phosphate 
group through electrostatic interaction. The distance between the side chain amine group 
of Lys888 and the α-phosphate is only 2.4 Å. The side chain amine group of Lys861 is 
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about 2.7 Å away from the α- and β-phosphates, interacting simultaneously with these 
two phosphate groups. Proper positioning of the side chains of Lys888 and Lys861 to 
interact with the α- and β-phosphate is facilitated by Asp872, which interacts with the 
side chains of these two residues through electrostatic interactions (Figure 2.9). The β-
phosphate also interacts with the side chains of Lys858 and His847 simultaneously 
(Figure 2.9). In addition, Lys858 also interacts with the γ-phosphate that is about 5 Å 
away from the side chain amine groups of Lys849 and Lys851 (Figure 2.9). These two 
positively charged residues may interact with the 5'-ppp through weak electrostatic 
interaction or solvent-mediated hydrogen bonds.  
Although the electrostatic interactions between RIG-I CTD and the 5'-ppp play 
dominant roles in dsRNA binding, RIG-I CTD interacts extensively with other parts of 
the dsRNA. The exposed base pair at each terminus of the dsRNA interacts with Phe853 
through hydrophobic interaction, and the guanine base at the 5'-end of the RNA stacks 
against the phenyl side chain of Phe853 (Figure 2.9).  The side chain of His830 forms a 
hydrogen bond with the 2'-hydroxyl group of nucleotide G2 (Figure 2.9). This hydroxyl 
group also forms two solvent-mediated hydrogen bonds with the backbone amine of 
Tyr831 and the carbonyl group of Ile887. The phosphate group of G2 forms two solvent-
mediated hydrogen bonds with Ser906 and Trp908. The third nucleotide C3 from the 5'-
end forms a solvent-mediated hydrogen bond with the backbone amine of Trp908. In 
addition, the phosphate group of G4 interacts with the side chain of Lys907 through 
electrostatic interactions (Figure 2.8). However, the RNA does not interact with the 
nearby Lys909 directly. The side chains of Lys849 and Lys851 are in close proximity to 
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the phosphate of C11 and G12 near the 3'-end of the RNA (Figure 2.8). However, the 
electron density map for the side chains of these two residues is poorly defined, 
reflecting their flexibility and limited contribution to dsRNA binding. The side chain 
hydroxyl of Ser854 forms a hydrogen bond with the 2'-hydroxyl at the 3'-terminal 
nucleotide (C14) of the complementary strand. Apart from the hydrophobic interactions 
between the terminal bases and Phe853, no other specific interaction between RIG-I 
CTD and the bases was observed in the two complex structures, demonstrating that RIG-
I CTD binds RNA in a sequence-independent manner. 
The detailed interactions between RIG-I CTD and the 14GC 5'-ppp dsRNA are 
listed in Table 2.3. 
 
RIG-I and LGP2 bind dsRNA with and without 5'-ppp in different ways 
The crystal structures of RIG-I and LGP2 CTD bound to dsRNA with and 
without 5'-ppp, respectively, allowed us to elucidate how the RLRs recognize these two 
different forms of dsRNA. To facilitate this comparison, we superimposed a14-bp 
dsRNA onto the structure of LGP2 CTD bound to an 8-bp dsRNA (74) (Figure 2.11).  
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Table 2.3 Interactions between RIG-I CTD and the 14-bp GC-rich 5'-ppp dsRNA. 
 
Nucleotide (ends) 
Atoms 
RIG-I CTD 
Atoms 
Distances 
(Å) 
Type of 
Interactions 
3pG1 (5') 
O2G 
O2B 
O2B 
O1B 
O2A 
O2A 
C2 
O2' 
O5' 
O3A 
O2' 
O2' 
O2' 
 
Lys858 NZ 
Lys858 NZ 
His847 NE2 
Lys861 NZ 
Lys861 NZ 
Lys888 NZ 
Phe853 CE2 
His830 ND1 
Gly874 CA 
Ile875 CG2 
Val886 CG1 
Tyr831 N (S1) 
Ile887 O (S1) 
 
3.4 
2.7 
2.6 
2.7 
2.7 
2.4 
3.2 
2.5 
3.8 
2.9 
3.9 
3.0 / 3.0 
3.0 / 3.0 
 
ES 
ES 
ES 
ES 
ES 
ES 
HP 
HB 
VDW 
VDW 
VDW 
sHB 
sHB 
G2 (5') 
O4' 
O2P 
O2P 
O2P 
O2P 
 
His830 CE1 
Lys888 CB 
Trp908 N (S21) 
Ser906 O (S32) 
Trp908 CD1 
 
3.3 
3.5 
2.6 / 3.0 
3.0 / 2.9 
3.2 
 
VDW 
VDW 
sHB 
sHB 
VDW 
C3 (5') 
O1P 
 
Trp908 N (S21) 
 
3.4/3.0 
 
sHB 
G4 (5') 
O2P 
 
Lys907 NZ 
 
3.2 
 
ES 
C11 (3') 
O1P 
 
Lys849 NZ 
 
2.7 
 
ES (?) 
C14 (3') 
O2' 
N3 
 
Ser854 OG 
Phe853 CB 
 
3.4 
3.9 
 
HB 
VDW 
HB: hydrogen bonds 
VDW: van der Waals contacts 
HP: hydrophobic interactions 
sHB: solvent mediated hydrogen bonds. Solvent distances to protein atoms and to 
dsRNA atoms are shown. 
ES: electrostatic interactions 
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Figure 2.11 Distinct binding by RIG-I and LGP2 CTDs to dsRNA with and without 5'-
ppp.  
Stereo representation of the structure of RIG-I CTD bound to the 14-bp GC-rich 5'-ppp 
dsRNA superimposed on the structure of LGP2 CTD bound to an 8-bp dsRNA without 
5'-ppp. The 14-bp 5'-ppp dsRNA bound to RIG-I CTD is shown as blue ribbons. The 8-
bp dsRNA bound to LGP2 CTD is colored magenta. A 14-bp dsRNA (orange) is 
superimposed on the 8-bp dsRNA in the LGP2 CTD:dsRNA complex structure to show 
the different orientations of the dsRNA relative to the proteins in the two complexes. 
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Superposition of LGP2 CTD onto the structure of RIG-I CTD bound to the 14-bp 
GC-rich dsRNA revealed that the orientations of the dsRNA in the two complexes are 
dramatically different (Figure 2.11). Although both proteins recognize the terminus of 
the dsRNA and similar binding surfaces are involved in RNA binding, the 14-bp 5'-ppp 
dsRNA was rotated by approximately 30 degrees away from RIG-I CTD compared to 
the 14-bp dsRNA in the LGP2 CTD:dsRNA complex model (Figure 2.11). As a result, 
RIG-I CTD has less-extensive interactions with the 5'-ppp dsRNA compared to the 
interactions between the non-ppp dsRNA and LGP2 CTD (74). The total buried surface 
area at the LGP2 CTD:dsRNA interface (about 1,540 Å2) is about 30% larger than that 
of the RIG-I CTD:dsRNA interface. The interface between LGP2 CTD and the non-ppp 
dsRNA also exhibits a higher degree of shape complementarity (Sc = 0.75).  
Although the interaction between LGP2 CTD and dsRNA is more extensive, the 
affinity of LGP2 CTD for a 10-bp blunt-ended dsRNA without ppp was about 100 nM 
(74). In addition, 5'-ppp dsRNA exhibits a slightly lower affinity for LGP2 CTD (74). 
Furthermore, mutations that disrupted RNA binding by LGP2 do not affect its ability to 
regulate RIG-I signaling (74). These results suggest that LGP2 does not regulate RIG-I 
signaling through direct competition with RIG-I for ligand binding, indicating that the 
RIG-I-RNA interaction is different from LGP2-RNA interaction. 
Since the 5'-ppp has to be positioned precisely into the ppp-binding site, this 
structural requirement determines the specific orientation of the 5'-ppp dsRNA relative 
to RIG-I CTD. Because the ppp makes primary contributions to 5'-ppp dsRNA binding 
by RIG-I CTD, the binding affinity of blunt-ended dsRNA without ppp should be much 
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lower than that of the 5'-ppp dsRNA; the buried surface area between a dsRNA without 
5'-ppp and RIG-I CTD will be reduced to about 1050 Å2 if the RNA still binds RIG-I in 
the same orientation. Interestingly, SPR binding studies show that RIG-I CTD binds the 
14-bp dsRNA without 5'-ppp at nanomolar affinity. It is possible that RIG-I CTD binds 
blunt-ended dsRNA lacking a ppp in a similar way as LGP2 CTD to increase the binding 
interactions. Because dsRNA with and without 5'-ppp both activate RIG-I in vivo, we 
propose that the two forms of RNA may trigger the activation of RIG-I through different 
mechanisms. 
 
Similar binding surfaces of RIG-I CTD mediate its interactions with different forms of 
RNA 
Based on the structures of RIG-I CTD bound to 5'-ppp dsRNA discussed above, 
we expressed and purified twelve mutant proteins of RIG-I CTD and studied their 
binding properties with a 5'-ppp dsRNA, a non-ppp dsRNA, and a 5'-ppp ssRNA by 
EMSA. Ten of these twelve mutants were also analyzed for RNA binding by gel 
filtration chromatography.  
First, mutations of each of the three positively charged lysine residues, Lys858, 
Lys861, and Lys888, that are involved in direct contact with the 5'-ppp to negatively 
charged glutamate residues almost abolished 5'-ppp dsRNA and ssRNA binding in the 
gel shift assays (Figure 2.12). Consistent with these results, no binding for 5'-ppp ssRNA 
and dsRNA were observed for these mutants by gel filtration chromatography (Figure 
2.13). Similarly, mutation of Lys888 to glutamate also abolished non-ppp dsRNA 
  
63 
binding (Figure 2.12). However, substitution of either Lys858 or Lys861 to glutamate 
dramatically reduced but did not abolish non-ppp dsRNA binding (Figure 2.12 and 
2.13). Substitution of His847 that interacts directly with the β-phosphate with glutamate 
significantly reduced the binding of 5'-ppp dsRNA and ssRNA, but only slightly reduced 
the binding of non-ppp dsRNA (Figure 2.12 and 2.13). Consistent with these results, 
mutations of both His847 and Lys861 to glutamate disrupted binding of 5'-ppp dsRNA 
or ssRNA and nearly abolished non-ppp dsRNA binding (Figure 2.12). 
Second, we analyzed the effects of mutations of four other positively charged 
residues--Lys849, Lys851, Lys907, and Lys909--on RNA binding. Mutation of Lys907 
that interacts with the phosphodiester backbone of the dsRNA to glutamate dramatically 
reduced RIG-I CTD binding for all three forms of RNA (Figure 2.12), demonstrating the 
critical role of this residue in recognizing the RNA backbone. Gel filtration 
chromatography confirmed that mutant K907E failed to bind all three forms of RNA 
(Figure 2.13).  In contrast, substitution of the nearby Lys909 with a glutamate reduced 
the binding of 5'-ppp dsRNA while almost abolished the binding of non-ppp dsRNA and 
5'-ppp ssRNA (Figure 2.12 and 2.13). Mutations of either Lys849 or Lys851 to 
glutamate reduced, but did not abolish, the binding for all three forms of RNA (Figure 
2.12 and 2.13). 
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Figure 2.12 Similar binding surfaces of RIG-I CTD mediate the interactions with 
different forms of RNA.  
(A) Binding studies of wild-type and mutants of RIG-I CTD for the 14-bp 5'-ppp dsRNA 
by EMSA.  
(B) Binding studies of RIG-I CTD and its mutants with a 14-bp dsRNA lacking 5'-ppp. 
(C) Binding studies of RIG-I CTD and its mutants with a 13-nt 5'-ppp ssRNA.
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Figure 2.13 Mutations of key residues in RIG-I CTD affect the binding of three different forms of RNA. 
(A) Binding studies of wild-type and mutants of RIG-I CTD for the 14-bp 5'-ppp dsRNA by gel filtration chromatography. 
Each of the chromatograms represents the elution profile of a 3:1 molar ratio mixture of RIG-I CTD or its mutants with the 
RNA. Elution volume of the protein and the RNA alone are shown above the chromatogram. Shift of the peak positions of 
mutant protein and RNA complexes relative to that of the wild-type protein or the RNA alone reflects how the mutation affect 
RNA binding. Mutants with no peak shift (such as K907E) do not bind RNA. RNA binding is not affected for mutant with 
peak shift (such as D872A) similar to that of the wild-type protein. 
(B) Binding studies of wild-type and mutants of RIG-I CTD for the 14-bp non-ppp dsRNA. 
(C) Binding studies of RIG-I CTD and its mutants for the 13-nt 5'-ppp ssRNA. 
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Third, we analyzed the mutations of His830, Phe853 and Asp872 that interact 
with the dsRNA through hydrogen bonding or hydrophobic interactions, or facilitate the 
binding of the ppp group. Replacement of Asp872 with an alanine did not affect RNA 
binding (Figure 2.12 and 2.13). Mutation of His830 to alanine did not affect 5'-ppp 
dsRNA or ssRNA binding, but reduced non-ppp dsRNA binding (Figure 2.13). Although 
the gel shift assays showed that substitution of Phe853 by serine did not affect RNA 
binding significantly (Figure 2.12), the gel filtration chromatography showed that this 
mutation dramatically reduced 5'-ppp RNA binding and nearly abolished non-ppp 
dsRNA binding (Figure 2.13).  
These mutagenesis and binding studies demonstrated that the binding surface 
observed in the complex structures mediates RNA binding by RIG-I CTD in solution. It 
is also important to note that, although similar binding surfaces are involved in 
contacting non-ppp dsRNA as well as 5'-ppp dsRNA and ssRNA, the fact that mutations 
in the CTD can differentially affect binding of the three forms of RNA illustrates distinct 
recognition of these RNA ligands by RIG-I. 
 
Mutations of key residues at the RNA-binding surface affect RIG-I signaling 
The twelve mutations tested for RNA binding were built into constructs of full-
length RIG-I to assess how these mutants affect RIG-I signaling in transiently 
transfected HEK 293T cells. The cells were first transfected to express the RIG-I 
mutants along with the IFN-β luciferase reporter plasmids. Expression of wild-type RIG-
I and various mutants in the transfected cells was confirmed by Western blot (Figure 
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2.14A). After 24 hours, different RNA ligands were transfected into the cells to analyze 
their abilities to activate RIG-I dependent signaling.  
First, we analyzed signaling of mutants modified at residues that play critical 
roles in the recognition of the 5'-ppp group. Because the Cα atom of Lys888 is only 3.8 
Å away from the G2 phosphate and its side chain amine group interacts with the α- 
phosphate of the 5'-ppp, substitution of Lys888 by glutamate disrupted RNA binding by 
RIG-I CTD and abolished RIG-I signaling by 5'-ppp dsRNA or ssRNA and non-ppp 
dsRNA as well (Figure 2.14). Although mutation of Lys861 to glutamate did not affect 
signaling by non-ppp dsRNA, it did disrupt signaling by 5'-ppp dsRNA and ssRNA 
(Figure 2.14). Similarly, mutation of Lys858 to glutamate reduced signaling by non-ppp 
dsRNA by about 50% and abolished signaling by 5'-ppp dsRNA and ssRNA (Figure 
2.14). Substitution of His847 by glutamate did not affect non-ppp dsRNA signaling, 
however it reduced signals from both 5'-ppp dsRNA and ssRNA dramatically (Figure 
2.14). 
Second, substitutions of Lys907 and Lys909 by glutamates disrupted signaling 
for all three forms of RNA (Figure 2.14). In contrast, mutations of either Lys851 or 849 
to glutamate did not affect any of the RNA signaling (Figure 2.14). 
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Figure 2.14 Mutations of key residues at the RNA binding surface affect RIG-I 
signaling. 
(A) Western blot showing the expression of wild-type and mutants of full-length RIG-I 
in transfected cells.  
(B) IFN-β luciferase assays showing the signaling of wild-type and mutants of RIG-I in 
HEK 293T cells stimulated with a 24-bp 5'-ppp dsRNA. Error bars correspond to the 
standard deviations of signals from three independent transfections. 
(C) IFN-β luciferase assays showing the signaling of wild-type and mutants of RIG-I in 
cells stimulated with a 27-nt 5'-ppp ssRNA. 
(D) IFN-β luciferase assay showing the signaling of wild-type and mutants of RIG-I in 
cells stimulated with a 27-bp dsRNA without 5'-ppp. 
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Third, we tested signaling of mutants of RIG-I at residues His830, Phe853 and 
Asp872 that have slightly reduced RNA binding. We found that mutations 
C829S/H830A or D872A had no effect on the signaling of RIG-I for any of the three 
forms of RNA tested (Figure 2.14). Consistent with these results, a Cys829 to serine 
substitution in RIG-I CTD did not affect RNA binding in vitro (Figure 2.13). The 
slightly higher activity of these two mutants compared to the wild-type protein is likely 
due to their higher expression level or better stability in the cells. However, replacement 
of the hydrophobic Phe853 by a hydrophilic serine reduced signaling of 5'-ppp dsRNA 
or ssRNA by about 70% and reduced signaling by dsRNA without 5'-ppp to background 
level (Figure 2.14), demonstrating that Phe853 has a role in RNA sensing by RIG-I. 
These results are consistent with RNA binding properties of RIG-I CTD mutants, 
demonstrating that RNA binding by RIG-I CTD is essential for RIG-I signaling and 
RNA with and without 5'-ppp can activate RIG-I in vivo.   
 
Discussion 
RNA binding studies showed that RIG-I CTD binds 5'-ppp dsRNA or ssRNA 
and non-ppp dsRNA, with the highest affinity for 5'-ppp dsRNA. IFN-β luciferase assays 
demonstrated that all three forms of RNA could stimulate RIG-I signaling. The 
structures of RIG-I CTD bound to 5'-ppp dsRNA showed that RIG-I recognizes the 
termini of RNA and interacts with the 5'-ppp as well as the backbone phosphodiesters of 
the RNA. Mutagenesis and RNA binding studies demonstrated that similar binding 
surfaces of RIG-I CTD are involved in the binding of various forms of RNA by RIG-I.  
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These results provide a structural framework to understand the RNA binding properties 
and functions of RIG-I in antiviral immune responses. 
 The complex structures showed that RIG-I CTD interacts primarily with the 5' 
four nucleotides of the dsRNA. The complementary RNA strand only makes limited 
contributions to RNA binding (Figure 2.8-2.10, and Table 2.3). These observations 
explain how RIG-I CTD can bind both dsRNA and ssRNA with 5'-ppp.  
The amino acid residues of RIG-I involved in RNA binding can be divided into 
three groups. The first group of residues includes Lys858, Lys861, Lys888, and His847 
that recognize the 5'-ppp of dsRNA. The second group of residues includes Lys907 and 
Lys909 that interact with the phosphate backbone of the dsRNA. The third group of 
residues interacts with the exposed bases at the termini of the RNA or interacts with the 
backbone of the RNA by hydrogen bonds. The first two groups of residues primarily 
contribute to RNA binding through multiple electrostatic interactions, whereas the third 
group of residues makes additional contributions to RNA binding through hydrogen 
bonds and hydrophobic interactions. All these residues contribute to the binding of RNA 
with 5'-ppp, while the last two groups of residues contribute primarily to the binding of 
dsRNA without 5'-ppp. Importantly, these structural features explain how RIG-I can 
recognize such a wide range of RNA ligands including 5'-ppp dsRNA and ssRNA, as 
well as dsRNA without 5'-ppp.  
The reason why ssRNA without 5'-ppp failed to bind RIG-I CTD is most likely 
due to the loss of the critical electrostatic interactions mediated by the ppp group. 
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However, dsRNA without ppp still binds to RIG-I CTD at high affinity. This is possibly 
due to the additional interactions between the complementary strand and the protein. 
Because the α- and β-phosphates make major contributions to the recognition of 
the 5'-ppp by RIG-I (Figure 2.9), the complex structures also explain why dsRNA with 
one or two 5'-terminal phosphates can serve as ligands for RIG-I. Previous studies 
showed that blunt-ended 5'-ppp dsRNA is a potent activator of RIG-I, whereas 5'-ppp 
dsRNA with 5'-overhangs still stimulated RIG-I but 5'-ppp dsRNA with 3'-overhangs 
failed to stimulate RIG-I (64). However, our RNA binding studies showed that all three 
forms of dsRNA bind RIG-I CTD efficiently (Figure 2.2). Although the complex 
structures indicated that dsRNA with 3'-overhangs can still bind RIG-I effectively, the 
reason why 5'-ppp dsRNA with 3'-overhangs failed to stimulate RIG-I is most likely that 
these RNA molecules are unwound by RIG-I (52). The structures suggest that 5'-ppp 
dsRNA with 5'-overhangs should exhibit significantly reduced affinity for RIG-I just 
like 5'-ppp ssRNA, explaining why this kind of RNA is less effective in stimulating the 
activation of RIG-I (64).  
Our binding studies showed that RIG-I CTD binds the GC- and AU-rich RNA 
with similar affinities. In addition, the two complex structures showed that RIG-I binds 
to the two kinds of RNA in almost the same way with no specific interactions between 
the protein and the bases (Figure 2.6A). These results indicate that RIG-I CTD is not 
responsible for the recognition of specific RNA sequences, such as the polyuridylates or 
polyadenylates sequences observed in the 3' untranslated regions of hepatitis C virus 
genome (97).  The studies by Chiu et al. showed that poly (dA-dT) DNA transfected in 
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cells can activate RIG-I as a result of transcription of these DNA sequences by RNA 
polymerase III, whereas GC-rich DNA failed to activate RIG-I when transfected into 
cells (98). This is not likely due to the different sequences of DNA but most likely due to 
the inefficient transcription of GC rich DNA by RNA polymerase III that need the poly 
(dA-dT) sequence to initiate transcription. In summary, the ability of RIG-I to recognize 
a broad range of RNA structures without sequence specificity allows the receptor to 
sense the infection of a wide spectrum of viruses.    
The crystal structures of RIG-I and LGP2 CTD in isolation and in complex with 
dsRNA are now available (60,72,74), as well as the solution structure of MDA5 CTD 
(73). These structures revealed that the CTD of the RLRs are highly conserved and 
similar binding surfaces are involved in RNA binding by all the three proteins (Figure 
2.7). The structures of RIG-I CTD and LGP2 CTD bound to dsRNA with and without 5'-
ppp demonstrated that the RLRs recognize the termini rather than the ribose-phosphate 
backbone of various forms of RNA (Figure 2.11). However, the three proteins exhibit 
different ligand-binding properties and play different roles in antiviral immune 
responses. Comparisons of the structures of RIG-I CTD in complex with 5'-ppp dsRNA 
and LGP2 CTD in complex with non-ppp dsRNA revealed that the orientations of the 
RNA are significantly different (Figure 2.11). This finding suggests that the 5'-ppp and 
non-ppp dsRNA interact with RIG-I differently and probably induce different 
conformations of full-length RIG-I upon binding. This idea is further supported by the 
differential binding of 5'-ppp dsRNA and non-ppp dsRNA by RIG-I CTD mutants 
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(Figure 2.12 and 2.13) and the ability of RIG-I mutants to activate luciferase reporters in 
cells stimulated with different forms of RNA (Figure 2.14). 
Comparisons of the ligand-binding surfaces of the RLR CTDs showed that the 
surface electrostatic potential of the three proteins are dramatically different (Figure 
2.15). For the four positively-charged residues in RIG-I CTD that are responsible for the 
5'-ppp recognition, only Lys888 is conserved in the sequences of LGP2 and MDA5 
CTDs (Figure 1.2). Consistent with this observation, both MDA5 and LGP2 CTDs bind 
5'-ppp dsRNA with lower affinities compared to blunt-ended dsRNA without 5'-ppp 
(74). It is evident that RIG-I is the only RLR that is responsible for the sensing of 5'-ppp 
RNA. Because RIG-I can also be activated by dsRNA without 5'-ppp, which is also 
recognized by MDA5, this could explain why RIG-I and MDA5 sense distinct but 
overlapping sets of viruses.   
 
 
 
Figure 2.15 Electrostatic surface potential of the RNA binding surfaces of RIG-I, LGP2, 
and MDA5 CTDs. 
Positively charged regions are colored blue, while negatively charged regions are red.  
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A number of factors may affect the results of RIG-I activation assays in vivo. The 
structure and purity of RNA ligands, their binding affinities for RIG-I, their effective 
concentrations in cells, and their stabilities will all affect the signal readout. Previous 
studies used various cell lines and different assays to demonstrate that various RNA 
ligands can activate signal transduction through RIG-I (90). Our studies demonstrated 
that dsRNA with and without 5'-ppp, and 5'-ppp ssRNA are the three major families of 
RNA that activate RIG-I. Furthermore, blunt-ended dsRNA with and without 5'-ppp are 
more effective agonists for RIG-I signaling than dsRNA with overhangs (52,64,74,90).  
Consistent with these findings, all these three families of RNA bind to RIG-I CTD, and 
blunt-ended dsRNA with 5'-ppp has a significantly higher affinity (Figure 2.1 and 2.4). 
Results from the IFN-β luciferase reporter assays confirmed that all these three families 
of RNA stimulate RIG-I signaling in cells (Figure 2.14).  In contrast, two recent studies 
showed that only dsRNA with 5'-ppp activate RIG-I in human monocytes (64,65). It is 
likely that the different assay techniques or the difference in the effective concentration 
of ligands in the transfected cells account for these discrepancies. Because the affinities 
of blunt-ended dsRNA without ppp and 5'-ppp ssRNA are about 15-fold lower than that 
of blunt-ended 5'-ppp dsRNA, significantly higher concentration of non-ppp dsRNA is 
needed for the activation of RIG-I. A number of other reports, including one of our 
previous studies, also demonstrated that dsRNA without 5'-ppp can activate RIG-I 
(52,74). In addition, it has been shown that RNase digestion of dsRNA mimetic poly I:C 
converts it from a ligand of MDA5 into a ligand for RIG-I (71). Moreover, the digestion 
of self-RNA by antiviral endonuclease RNase L generates small RNA products that 
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initiate interferon production (30).  It is likely that higher concentration of ligands 
generated by RNase digestion triggers the activation of RIG-I.  
Structural studies of RIG-I and LGP2 CTD bound to dsRNA provided important 
insights into the structural basis of viral RNA recognition by the RLRs. However, the 
mechanism of how RNA binding triggers the activation of RIG-I or MDA5 remains to 
be established. Although electron microscopy studies of RIG-I and LGP2 in isolation 
and in complex with dsRNA provided some information about how these proteins might 
bind RNA (99,100), the detailed mechanism of how RNA binding activates the RLRs 
awaits the determination of high resolution structures of the full-length proteins bound to 
RNA. 
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CHAPTER III 
STRUCTURAL BASIS OF THE INTERACTIONS BETWEEN BLUNT-ENDED 
DOUBLE-STRANDED RNA WITHOUT 5'-TRIPHOSPHATE AND RIG-I C-
TERMINAL DOMAIN*  
 
Background 
 RIG-I recognizes molecular patterns in viral RNA to regulate the induction of 
type I IFNs. Since RNA can fold into complicated three-dimensional structures and 
contain various modifications, especially at their termini, it is not clear what the exact 
structural feature of the viral RNA is recognized by RIG-I and how RNA binding 
activates RIG-I signaling.  
 RNA transcripts containing a 5'-ppp potently trigger the activation of RIG-I upon 
transfection into cells (61,62). Recent studies using chemically synthesized dsRNA or 
hairpin RNA containing 5'-ppp further demonstrated that base pairing near the 5'-ppp is 
necessary for RIG-I activation (64,65,101). Moreover, blunt-ended dsRNA without 5'-
ppp can also activate RIG-I signaling in transfected cells (66,74). In addition, digestion  
 
 
____________ 
*Reproduced with permission from “Crystal structures of RIG-I C-terminal domain 
bound to blunt-ended double-strand RNA without 5' triphosphate” by Lu C., Ranjith-
Kumar C.T., Hao L., Kao C.C., and Li P. 2011. Nucleic Acids Research. 39, 1565-1575. 
Copyright (2011) by Oxford University Press. 
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of the dsRNA mimetic poly I:C by RNase III to fragments of <1 kb transforms poly I:C 
from an activator of MDA5 to an activator of RIG-I (71). Consistent with this, short 
RNA generated by RNase L digestion of cellular RNA induced IFN production via RIG-
I and MDA5 (30). These results indicated that the 5'-ppp is not absolutely needed for the 
activation of RIG-I by RNA. Clearly, how RIG-I recognizes such a wide range of 
ligands need to be better defined.  
Studies in Chapter II showed that the CTD of RIG-I exhibits high affinity for 5'-
ppp dsRNA as well as non-ppp dsRNA. The crystal structure of LGP2 CTD bound to an 
8-bp blunt-ended non-ppp dsRNA provided the first evidence that the termini of dsRNA 
are recognized by the RLRs (74). Structures of RIG-I CTD bound to the 14-bp GC-rich 
and the 12-bp AU-rich 5'-ppp dsRNA confirmed that RIG-I CTD also recognizes the 
termini of 5'-ppp dsRNA, and interacts with the ppp group through electrostatic 
interactions. A similar mode of RNA binding was observed in the structure of RIG-I 
CTD bound to a different 12-bp dsRNA (102). These structures showed that the 5'-ppp 
of the dsRNA is recognized by a cluster of positively charged residues including 
Lys858, Lys861, Lys888, and His847. In contrast, both MDA5 and LGP2 CTDs bind to 
blunt-ended dsRNA with no preference for 5'-ppp group. Consistent with this, structures 
of MDA5 and LGP2 CTDs showed that these two proteins lack the ppp-binding site 
observed in RIG-I CTD. Comparisons of the structures of RIG-I CTD bound to 5'-ppp 
dsRNA and LGP2 CTD bound to non-ppp dsRNA showed that the dsRNA were in 
dramatically different orientations. These observations led us to hypothesize that RIG-I 
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CTD will bind non-ppp dsRNA and 5'-ppp dsRNA in different ways. However, the 
structural basis for the recognition of non-ppp dsRNA by RIG-I is not fully understood. 
To understand to promiscuous RNA binding by RIG-I, we determined the crystal 
structure of RIG-I CTD bound to a 14-bp non-ppp dsRNA at 2.4-Å resolution and 
compared the structure of RIG-I CTD bound to 5'-ppp dsRNA of the same sequence. 
These two structures revealed that distinct but overlapping sets of residues are involved 
in the binding of dsRNA with and without 5'-ppp. The orientation of non-ppp dsRNA 
relative to RIG-I CTD is dramatically different from that of the 5'-ppp dsRNA. 
Mutagenesis of key residues at the RNA-binding surface affected RNA binding in vitro 
and RIG-I signaling in vivo. 
 
Materials and methods 
RNA binding studies 
Human RIG-I CTD was expressed and purified as described in Chapter II. 
Different forms of RNA were generated either by chemical synthesis (IDT) or by in vitro 
transcription using T7 RNA polymerase as described in Chapter II. The in vitro 
transcribed RNA were purified by gel filtration chromatography and analyzed by 
denaturing PAGE. Sequences of all the RNA and DNA oligos used in this study are 
shown in Table 3.1. All the dsRNA used were generated by annealing of the ssRNA, as 
described in Chapter II.  
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Table 3.1 Sequences of RNA and DNA used in this study. 
The 5'-ppp RNA were synthesized by in vitro transcription and purified by gel filtration 
chromatography or denaturing PAGE. The dsRNA without 5'-ppp were chemically 
synthesized by IDT.  
 
14-bp GC-rich 5'-ppp 
dsRNA 
5' pppGGCGCGCGCGCGCC 3' 
   3' CCGCGCGCGCGCGGppp 5' 
14-bp blunt-ended dsRNA 
without 5'-ppp 
5' GGCGCGCGCGCGCC 3' 
3' CCGCGCGCGCGCGG 5' 
14-bp blunt-ended dsDNA 5' GGCGCGCGCGCGCC 3' 
3' CCGCGCGCGCGCGG 5' 
13-nt 5'-ppp ssRNA 5' pppGGCGCAUAGGCCG 3' 
13-bp RNA:DNA hybrid 5' GGCGCAUAGGCCG 3' (RNA) 
3' CCGCGTATCCGGC 5' (DNA) 
14-bp dsRNA with 5'-
overhangs 
5' AUAUGGCGCGCGCGCGCC 3' 
    3' CCGCGCGCGCGCGGUAUA 5' 
14-bp dsRNA with 3'-
overhangs 
 5'    GGCGCGCGCGCGCCAUAU 3' 
3' UAUACCGCGCGCGCGCGG 5' 
24-bp 5'-ppp dsRNA 5' pppGGCGCGCGAGUCGACUCGCGCGCC 3' 
   3' CCGCGCGCUCAGCUGAGCGCGCGGppp 5' 
27-nt 5'-ppp ssRNA 5' pppGGUGCAGAUGAACUUCAGGGUCAGCUU 3' 
27-bp blunt-ended dsRNA 
without 5'-ppp 
5' AAGCUGACCCUGAAGUUCAUCUGCACC 3' 
3' UUCGACUGGGACUUCAAGUAGACGUGG 5' 
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In the binding studies by gel filtration chromatography, the RNA samples (at 
about 100 μM) were mixed with equal volume of RIG-I CTD (at about 200 μM) and 100 
μl of samples were injected over a Superdex200 (10/300 GL) column (GE Healthcare) 
eluted with the Tris-NaCl buffer.  
In the binding studies by EMSA, each type of RNA was mixed with RIG-I CTD 
at a molar ratio 1:3 at a final concentration of about 1.6:5 μM. The mixtures were 
resolved on 12% native polyacrylamide gels and stained with EtBr.  
 
Purification, crystallization and structural determination of RIG-I CTD and 14-bp 
dsRNA complex 
Human RIG-I CTD was expressed and purified as described in Chapter II. The 
14-bp blunt-ended non-ppp dsRNA (Table 3.1) was chemically synthesized by IDT. The 
dsRNA was mixed with excess RIG-I CTD and the 2:1 (RIG-I CTD:dsRNA) complex 
was purified by gel filtration chromatography on a Superdex75 (1.6 × 60) column (GE 
Healthcare).  
The complex was concentrated to about 10 mg/ml and crystallized in 27% PEG 
500 monomethyl ether (PEG MME 500) in 0.1 M HEPES buffer at pH 7.5. The crystals 
were flash frozen in liquid nitrogen.  
Diffraction data were collected using a Rigaku RAXIS IV++ detector and 
processed with HKL2000 (92). The complex crystallizes in space group P212121 with 
cell dimensions: a = 36.99 Å, b = 70.30 Å, c = 125.54 Å. The crystallographic ASU 
contains one 2:1 (RIG-I CTD:dsRNA) complex. Structure of RIG-I CTD in the complex 
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was determined by molecular replacement with MOLREP (94) using the structure of 
RIG-I CTD bound to the 14-bp 5'-ppp dsRNA (as described in Chapter II) as search 
model (PDB code: 3LRN). The structural model was rebuilt using O (95). After several 
rounds of refinement with CNS (93), electron density for the dsRNA became obvious. A 
14-bp dsRNA was manually docked into the electron density map and rebuilt with O. 
The structure was refined using CNS.  
The atomic coordinates and structure factors of RIG-I CTD bound to the 14-bp 
non-ppp dsRNA have been deposited with the RCSB Protein Data Bank under the 
accession code 3OG8. The structural figures were generated with PyMol 
(http:///www.pymol.org).  
 
Mutagenesis studies of dsRNA binding surface of RIG-I CTD 
For dsRNA binding surface analysis, 4 residues were mutated for binding 
studies. Point mutations were introduced by PCR using a QuikChange Site-Directed 
Mutagenesis kit (Stratagene). DNA primers (IDT) used in this study were: 
For R811E 
Forward primer  
5'- GGAAAATAAAAAACTGCTCTGCGAGAAGTGCAAAGCCTTGGCATGTT -3'  
Reverse primer 
5'- AACATGCCAAGGCTTTGCACTTCTCGCAGAGCAGTTTTTTATTTTCC -3' 
For R811S 
Forward primer 5'- AAAAAACTGCTCTGCAGCAAGTGCAAAGCCTTGGC -3'  
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Reverse primer 5'- GCCAAGGCTTTGCACTTGCTGCAGAGCAGTTTTTT -3' 
For R812E 
Forward primer  
5'- AAAATAAAAAACTGCTCTGCAGAGAGTGCAAAGCCTTGGC -3'  
Reverse primer 5'- GCCAAGGCTTTGCACTCTCTGCAGAGCAGTTTTTTATTTT -3' 
For R812S 
Forward primer  
5'- AAAAAACTGCTCTGCAGAAGCTGCAAAGCCTTGGCATGT -3'  
Reverse primer 5'- ACATGCCAAGGCTTTGCAGCTTCTGCAGAGCAGTTTTTT -3' 
For R866E 
Forward primer  
5'- GAGCAAAGATATTCTGTGCCGAGCAGAACTGCAGCCATGACTG -3'  
Reverse primer  
5'- CAGTCATGGCTGCAGTTCTGCTCGGCACAGAATATCTTTGCTC -3' 
For H871E 
Forward primer 5'- CCGACAGAACTGCAGCGAGGACTGGGGAATCCATG -3'  
Reverse primer 5'- CATGGATTCCCCAGTCCTCGCTGCAGTTCTGTCGG -3' 
Sequences of the mutants were confirmed by plasmid DNA sequencing (Institute 
of plant genomics and biotechnology, Texas A&M University). 
The mutant proteins were expressed and purified the same way as the wild-type 
protein. RNA binding studies for the mutants were conducted by EMSA and gel 
filtration chromatography. 
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Mutagenesis of RIG-I and IFN-β luciferase reporter gene assays   
IFN-β luciferase reporter gene assays were used to analyze the effects of 
mutations at RNA-binding surface on RIG-I signaling in HEK 293T cells, with the helps 
from our collaborators at the Indiana University, Bloomington (Dr. C. Cheng Kao group, 
Department of Molecular and Cellular Biochemistry), according to the methods 
described in Chapter II. Briefly, the cells were transfected with plasmid of wild-type 
RIG-I or its mutans along with IFN-β luciferase reporter plasmid and Renilla luciferase 
control plasmid. After 24 hr, three different forms of RNA (Table 3.1) at 50 nM 
concentrations were transfected into the cells to stimulate RIG-I dependent signaling. 
The ratios of firefly luciferase reporter over Renilla luciferase control were determined.  
Mutations of full-length RIG-I were performed using pUNO-hRIG-I (Invivogen) 
as template. Expression of wild-type and mutants of RIG-I in the transfected cells were 
confirmed by western blot using anti-RIG-I antibody (C-15, sc-48929, Santa Cruz 
biotechnology). 
 
Results 
RIG-I CTD binds to blunt-ended dsRNA without 5'-ppp 
We chemically synthesized a 14-bp blunt-ended dsRNA, two 14-bp dsRNA with 
either 5'- or 3'-overhangs, a 14-bp dsDNA, and a 13-bp RNA:DNA hybrid (Table 3.1), 
and studied their binding interactions with RIG-I CTD by both gel filtration 
chromatography and EMSA. 
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As discussed in Chapter II, gel filtration chromatography showed that RIG-I 
CTD binds to the blunt-ended non-ppp dsRNA and forms a stable complex (Figure 2.1D 
and 3.1A). Based on the gel filtration chromatograms of the RIG-I CTD:dsRNA 
mixtures at different molar ratios (Figure 3.1A), the stoichiometry between RIG-I CTD 
and the 14-bp blunt-ended dsRNA is estimated to be 2:1. Binding studies by EMSA also 
showed that RIG-I CTD binds to blunt-ended non-ppp dsRNA as well as 5'-ppp dsRNA 
(Figure 3.1F).  
However, the 14-bp non-ppp dsRNA with 5'-overhangs failed to bind RIG-I CTD 
(Figure 3.1B and F). Although the dsRNA with 3'-overhangs still binds to RIG-I CTD by 
EMSA (Figure 3.1F), gel filtration chromatography showed that it binds to RIG-I CTD 
with reduced affinity and does not form the stoichiometric 2:1 complex (Figure 3.1C).  
In addition, gel filtration chromatography showed that RIG-I CTD does not bind 
a 14-bp dsDNA with the same sequence as the 14-bp blunt-ended dsRNA (Figure 3.1D). 
Furthermore, a 13-bp blunt-ended RNA:DNA hybrid also binds to RIG-I CTD (Figure 
3.1E). The stoichiometry between RIG-I CTD and the RNA:DNA hybrid is estimated to 
be 1:1. 
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Figure 3.1 RIG-I CTD binds to blunt-ended dsRNA without 5'-ppp. 
(A) Binding studies of RIG-I CTD with the 14-bp blunt-ended dsRNA by gel filtration 
chromatography. RIG-I CTD, the 14-bp blunt-ended dsRNA, and mixtures of RIG-I 
CTD:dsRNA at molar ratios 1:1 to 4:1 were injected over a superdex200 column. 
Elution profile of RIG-I CTD is in black and the dsRNA in red. Elution profiles of 
mixtures of RIG-I CTD and the 14-bp dsRNA at molar ratios 1:1, 2:1, 3:1, and 4:1 are in 
green, blue, cyan, and purple, respectively. The molecular masses of four protein 
standards and their elution positions are shown above the chromatograms.  
(B) Binding studies of RIG-I CTD with a 14-bp dsRNA containing 5'-AUAU overhangs.  
(C) Binding studies of RIG-I CTD with a 14-bp dsRNA containing 3'-AUAU overhangs.  
(D) Binding studies of RIG-I CTD with a 14-bp blunt-ended dsDNA with the same 
sequence as the 14-bp blunt-ended dsRNA. 
(E) Binding studies of RIG-I CTD with a 13-bp RNA:DNA hybrid.   
(F) Binding studies of RIG-I CTD with the 14-bp 5'-ppp dsRNA, 14-bp blunt-ended 
non-ppp dsRNA, and 14-bp non-ppp dsRNA with either 5'- or 3'-overhangs by EMSA. 
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Table 3.2 Statistics of crystallographic analysis. 
 
Diffraction Data  
Space group P212121 
Unit cell a = 36.99 Å, b = 70.30 Å, c = 125.54 Å 
Asymmetric unit One 2:1 RIG-I CTD:dsRNA complex 
Resolution (Å) 50.0-2.40 (2.49-2.40)a 
Unique reflections 13384 
Redundancy 6.0 (5.8) 
Completeness (%) 99.1 (98.0) 
I/σI 29.5 (5.3) 
Rsym (%) 8.6 (44.8) 
Refinement  
Resolution (Å) 50.0-2.40 
Reflections (F > 0) (total/test set) 12860/1329 
No. of atoms 
Protein 
RNA 
Zinc Ion 
Solvent 
 
20998 
596 
2 
133 
Rcryst/Rfree (%) 22.1/28.5 
R.m.s.d. bond length 
R.m.s.d. bond angle 
0.006 Å 
1.32° 
a Values in the parentheses are for the highest-resolution shell; 10% of reflections are used 
in the test set for Rfree calculation. 
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Figure 3.2 Crystal structure of human RIG-I CTD bound to a 14-bp blunt-ended dsRNA 
without 5'-ppp (PDB code 3OG8).  
(A) Structure of RIG-I CTD bound to the dsRNA. RIG-I CTDs are shown by the green 
ribbons. The dsRNA is shown by the sticks representation. Carbon atoms of the two 
RNA strands are colored cyan and pink, respectively. The zinc ion bound to RIG-I CTD 
is shown by the gray sphere. The complex exhibits pseudo two-fold non-crystallographic 
symmetry. The pseudo two-fold axis is shown by the black oval. 
(B) Stereo representation of the σA weighted 2Fo - Fc map (orange mesh, contoured at 
1.0σ) for the 14-bp blunt-ended non-ppp dsRNA bound to RIG-I CTD. The dsRNA is 
shown as pink and cyan ball-and-stick models. RIG-I CTD is shown as green ribbons. 
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Crystal structure of RIG-I CTD bound to blunt-ended non-ppp dsRNA 
To elucidate the structural basis of non-ppp dsRNA recognition by RIG-I, we 
cocrystallized RIG-I CTD (residues 803 to 923) with a 14-bp blunt-ended dsRNA. The 
crystal structure of the complex was determined by molecular replacement and refined at 
2.40-Å resolution (PDB code 3OG8). Statistics of data collection and structural 
refinement are shown in Table 3.2. 
The overall structure of the complex crystal is shown in Figure 3.2. Each 
crystallographic ASU contains a 2:1 complex between RIG-I CTD and the dsRNA. The 
structure showed that one RIG-I CTD bound to each terminus of the blunt-ended dsRNA, 
forming a complex with pseudo two-fold symmetry (Figure 3.2A). Structures of the two 
RIG-I CTDs in the complex are essentially the same (r.m.s.d 0.6 Å) and the two RIG-I 
CTDs bind to the dsRNA in similar ways. Discussions of the structure will be based on 
the interface between RIG-I CTD chain A and the dsRNA due to better-defined electron 
density throughout this interface (Figure 3.2B). 
The overall structure of the RIG-I CTD:dsRNA complex looks like two hands 
holding a stack of chips (Figure 3.2A). The exposed base pairs at the termini of the 
dsRNA stack on the loop connecting strands β5 and β6 (loop 5-6), and interact with 
RIG-I CTD through hydrophobic interactions. The thumb, corresponding to the loop 
connecting strand β10 and the C-terminal helix, reaches into the major groove of the 
dsRNA and interacts with the RNA through electrostatic interactions.  
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Figure 3.3 Surface electrostatics of RIG-I CTD.  
Positively charged surface is colored blue and negatively charged surface red. The blunt-
ended non-ppp dsRNA bound to RIG-I CTD is shown by the stick models. Key residues 
mediating non-ppp dsRNA recognition are labeled. Location of the ppp-binding site for 
5'-ppp dsRNA is indicated by the white asterisk. 
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Figure 3.4 Structural basis of blunt-ended non-ppp dsRNA recognition by RIG-I CTD.  
 (A) Interactions between the 5' four nucleotides of the 14-bp blunt-ended non-ppp 
dsRNA and RIG-I CTD. The dsRNA is shown by the stick models. Carbon atoms of the 
RNA strand interacting with RIG-I CTD are colored cyan. The complementary strand is 
colored light gray. RIG-I CTD is shown by the green ribbons. Key residues involved in 
RNA binding are shown by the magenta stick models.  
(B) Interactions between complementary strand and RIG-I CTD. The complementary 
strand of the RNA is shown by the stick models with carbon atoms colored pink.  
(C) Schematic representations of the interactions between RIG-I CTD and the 14-bp 
non-ppp dsRNA (left) or the 14-bp 5'-ppp dsRNA (right). Interactions between the 
dsRNA and one of the two RIG-I CTD molecules are shown. 
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Table 3.3 Interactions between RIG-I CTD and the 14-bp non-ppp dsRNA. 
Nucleotide (termini) 
Atoms 
RIG-I CTD 
Atoms 
Distances 
(Å) 
Type of 
Interactions 
G1 (5') 
O2' 
N3 
O6 
O4' 
C5' 
O5' 
O2' 
O2' 
 
His830 ND1 
Phe853 CE2 
Lys858 NZ 
Ile875 CD1 
Val886 O 
Gly874 CA 
Tyr831 N (S30) 
Ile887 O (S30) 
 
2.7 
3.2 
2.7 
3.4 
3.0  
3.5 
2.9/2.7 
2.9/2.8 
 
HB 
HP 
HB 
VDW 
VDW 
VDW 
sHB 
sHB 
G2 (5') 
O1P 
O2P 
O4' 
O1P 
O1P 
O1P 
 
Trp908 CD1 
Lys888 CB 
His830 CE1 
Glu890 N (S1)* 
Ser906 O (S1) 
Trp908 N (S107) 
 
3.2 
3.6 
3.6 
2.8/3.2 
2.8/3.3 
2.9/2.9 
 
VDW 
VDW 
VDW 
sHB 
sHB 
sHB 
C3 (5') 
O2P 
O2P 
O1P 
 
Lys907 CD 
Lys909 N (S46) 
Trp908 N (S107) 
 
3.4 
2.6/2.8 
2.8/2.9 
 
VDW 
sHB 
sHB 
G4 (5') 
O2P 
 
Lys907 NZ 
 
3.1 
 
ES 
C5 (3') 
O3' 
 
Leu904 O(S81) 
 
3.4/3.4 
 
sHB 
C6 (3') 
O1P 
O1P 
 
Arg811 NH2 (S61) 
Ser906 O (S61) 
 
2.8/2.6 
2.8/3.3 
 
sHB 
sHB 
C7 (3') 
O1P 
O2P 
 
Arg811 NH2 
Arg811 NE 
 
3.7 
3.0 
 
ES 
ES 
G8 (3') 
O1P 
 
His871 NE2 
 
4.1 
 
ES 
C11 (3') 
O1P 
 
Lys849 NZ 
 
3.4 
 
ES (?) 
G12 (3') 
O2P 
 
Lys849 NZ 
 
3.5 
 
ES (?) 
G14 (3') 
O1P 
N4 
 
Lys851 NZ 
Phe853 CB 
 
3.7 
3.3 
 
ES  
HP 
HB: hydrogen bonds 
VDW: van der Waals contacts 
HP: hydrophobic interactions 
sHB: solvent mediated hydrogen bonds. Solvent distances to protein atoms and to 
dsRNA atoms are shown. * Solvent molecules mediating the hydrogen bonds. 
ES: electrostatic interactions 
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The structure of RIG-I CTD shows shape and charge complementarity with the 
first-turn of the blunt-ended dsRNA (Figure 3.3). The average Sc of 0.67 between the 
two interfaces shows a better match compared to the interface between RIG-I CTD and 
5'-ppp dsRNA (Sc = 0.62, Chapter II), where an Sc value of 1.0 indicates a perfect fit 
between two interacting surfaces (96). 
The 5' four nucleotides of the dsRNA make major contributions to RNA binding, 
contributing to about 770 Å2 of buried surface area (Figure 3.4A). However, unlike 
similar dsRNA with 5'-ppp, the complementary strand also makes significant 
contribution to the binding (buried surface area of about 540 Å2) (Figure 3.4B and C). 
The total buried surface area at the non-ppp dsRNA:RIG-I CTD interface (about 1310 
Å2) is slightly larger than that at the 5'-ppp dsRNA: RIG-I CTD interface (about 1200 Å2, 
Chapter II). 
 
Interactions between RIG-I CTD and the non-ppp dsRNA 
The interaction between the blunt-ended non-ppp dsRNA and RIG-I CTD 
contains a mixture of electrostatic, direct and solvent mediated hydrogen bonding, 
hydrophobic and van der Waals interactions (Table 3.3).  
The first four nucleotides at the 5' end of the dsRNA interact with RIG-I CTD in 
a similar manner as dsRNA containing 5'-ppp (Figure 3.4A). The 2'-hydroxyl of 
nucleotide G1 forms a hydrogen bond with the side chain of His830. This is the only 
direct contact between the ribose and the protein. This hydroxyl group also forms two 
solvent-mediated hydrogen bonds with backbone amine and carbonyl groups of Tyr831 
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and Ile887. This ribose also has van der Waals contacts with two hydrophobic residues 
Val886 and Ile875. The second nucleotide (G2) interacts with RIG-I CTD through three 
solvent-mediated hydrogen bonds with residues Ser906, Trp908, and Glu890. G2 also 
has van der Waals contacts with Lys888 and His830. The third nucleotide C3 interacts 
with RIG-I CTD mainly through solvent mediated hydrogen bonds between its 
phosphodiester and the backbone amines of Trp908 and Lys909. The side chain amine 
of Lys907 interacts with the phosphodiester of G4 through electrostatic interactions 
(Figure 3.4A and C). Although similar interactions were also observed in the complex 
between 5'-ppp dsRNA and RIG-I CTD, the 5'-ppp makes additional electrostatic 
interactions with RIG-I CTD (Figure 3.4C). 
Several nucleotides from the complementary strand also make significant 
contributions to blunt-ended dsRNA binding (Figure 3.4B and C). Key contributions 
likely come from positively charged Arg811 and His871 that interact with the 
phosphodiester of C7 and G8 through electrostatic interactions. Notably, these 
interactions are not observed in the structures of 5'-ppp dsRNA bound to RIG-I CTD 
(Figure 3.4C). The side chain of Lys849 is within 4 Å of the phosphodiester of C11 and 
G12, and might interact with the RNA through additional electrostatic interactions. 
Moreover, the side chain amine of Lys851 is 3.7 Å away from the phosphate of C14 and 
interacts with the RNA through electrostatic interactions. Apart from these electrostatic 
interactions, three solvent mediated hydrogen bonds are observed between nucleotides 
C5 and G6 and residues Leu904, Arg811 and Ser906. 
 
  
97 
 
Figure 3.5 RNA binding studies of RIG-I CTD mutants by EMSA.  
(A) Binding studies of wild-type and mutants of RIG-I CTD with the 14-bp blunt-ended 
non-ppp dsRNA.  
(B) Binding studies of wild-type and mutants of RIG-I CTD with a 14-bp 5'-ppp dsRNA.  
(C) Binding studies of wild-type and mutants of RIG-I CTD with a 13-nt 5'-ppp ssRNA. 
(D) Binding studies of RIG-I CTD mutants K812E and K812S by EMSA. 
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Figure 3.6 RNA binding studies of RIG-I CTD mutants by gel filtration chromatography.  
(A) Binding studies of wild-type and mutants of RIG-I CTD with the 14-bp 5'-ppp 
dsRNA.  
(B) Binding studies of wild-type and mutants of RIG-I CTD with the 14-bp blunt-ended 
non-ppp dsRNA.  
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The exposed GC base pair at the termini of the dsRNA interacts with RIG-I CTD 
primarily through hydrophobic interactions by stacking its guanine ring on the phenyl 
side chain of Phe853 (Figure 3.4A). The guanine base also forms a hydrogen bond with 
the side chain of Lys858. A purine base at the 5'-terminus of the dsRNA should stack 
more effectively on the phenyl ring of Phe853 than a pyrimidine base. 
 
Mutagenesis studies of non-ppp dsRNA binding surface of RIG-I CTD 
The structure of RIG-I CTD bound to the blunt-ended non-ppp dsRNA indicates 
that residues Arg811, Lys812 and His871 may play critical roles in the specific binding 
of non-ppp dsRNA. To test this prediction, we purified RIG-I CTD mutants R811E, 
R811S, K812E, K812S, H871E, and R866E as a control, and conducted RNA binding 
studies by EMSA (Figure 3.5) and gel filtration chromatography (Figure 3.6). 
Substitution of Arg811 with glutamate almost abolished blunt-ended non-ppp 
dsRNA binding and significantly reduced binding to both 5'-ppp dsRNA and ssRNA 
(Figure 3.5). Replacement of Arg811 by a hydrophilic serine reduced the binding of 
blunt-ended dsRNA, but did not affect binding to 5'-ppp dsRNA or ssRNA (Figure 3.5). 
Substitution of the nearby Lys812 by glutamate dramatically reduced non-ppp dsRNA 
binding, but only slightly reduced binding to 5'-ppp dsRNA or ssRNA (Figure 3.5). 
Replacement of Lys812 by a neutral serine residue did not affect RNA binding (Figure 
3.5D). Surprisingly, the replacement of His871 by glutamate did not affect the binding to 
all three forms of RNA (Figure 3.5), suggesting that the His871 makes only minimal 
contribution to RNA binding. As expected, the replacement of Arg866, a residue not at 
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the RNA binding surface, by glutamate did not affect RNA binding (Figure 3.5). The 
slightly slower migration of the R866E and H871E complex is likely due to the changes 
of the surface electrostatics of the mutant proteins.  
In addition, studies in Chapter II showed that mutation K907E disrupted non-ppp 
dsRNA as well as 5'-ppp dsRNA binding (Figure 2.12). Together, these results suggest 
that the electrostatic interactions between Arg811 and Lys907 and the dsRNA are 
essential for non-ppp dsRNA binding. Furthermore, studies in Chapter II showed that 
substitution of Phe853 by serine also reduced dsRNA binding (Figure 2.12), suggesting 
the hydrophobic interaction between Phe853 and the exposed base pair is also needed for 
effective RNA binding. 
 
Blunt-ended dsRNA with and without 5'-ppp bind RIG-I CTD in different orientations 
The crystal structures of dsRNA with and without 5'-ppp bound to RIG-I CTD 
(Chapter II and this chapter) revealed that RIG-I CTD binds 5'-ppp and non-ppp dsRNA 
in dramatically different ways (Figure 3.7). The non-ppp dsRNA needs to swing towards 
RIG-I CTD by about 15° relative to the 5'-ppp dsRNA to increase its contacts with the 
protein. Surprisingly, the interactions between the 5' four nucleotides of the non-ppp 
dsRNA and RIG-I CTD are similar to those observed in the structures of 5'-ppp dsRNA 
bound to RIG-I CTD. No rotation along the helical axis of the dsRNA is necessary for 
RIG-I CTD to interact with these two different forms of dsRNA. It is obvious that the 
specific interactions between the ppp and RIG-I CTD determine how 5'-ppp dsRNA 
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binds to RIG-I CTD, while the interactions between the phosphodiester backbones of the 
dsRNA and the protein determine how the non-ppp dsRNA binds.  
Superposition of RIG-I CTD in the two complexes showed that the structures of 
RIG-I CTD are almost the same (r.m.s.d. 0.5 Å) (Figure 3.7), indicating only minor 
conformational adjustment of RIG-I CTD is needed to bind these two forms of RNA. 
These structures show that RIG-I CTD is a versatile RNA binding module that uses 
similar binding surfaces to recognize different forms of RNA.  
 
 
 
 
Figure 3.7 Superposition of RIG-I CTD bound to 14-bp blunt-ended dsRNA with and 
without 5'-ppp.  
RIG-I CTD bound to the non-ppp dsRNA (blue) and the 5'-ppp dsRNA (red) are shown 
by the green and cyan ribbons, respectively. 
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Comparison of RIG-I and LGP2 CTDs bound to blunt-ended dsRNA 
Superposition of the structures of RIG-I and LGP2 CTDs bound to blunt-ended 
non-ppp dsRNA showed that the non-ppp dsRNA bind to the two CTDs in significantly 
different orientations as well (Figure 3.8). The interaction between LGP2 CTD and the 
dsRNA is more extensive (buried surface area of about 1540 Å2) and shows a slightly 
higher shape complementarity (Sc = 0.70) (74). To bind the LGP2 CTD, the dsRNA 
needs to rotate along its helical axis and swing towards the protein by about 15° relative 
to the position of the non-ppp dsRNA bound to RIG-I CTD (Figure 3.8). Even though 
the overall structures of RIG-I and LGP2 CTDs bound to dsRNA are similar (r.m.s.d. 
1.35 Å), the conformations of loop5-6 that contact the exposed base pairs are quite 
different (Figure 3.8).  
The surface electrostatics of RIG-I and LGP2 CTDs are also dramatically 
different (Figure 3.9). Critical residues Arg811 and His871 involved in blunt-ended non-
ppp dsRNA binding by RIG-I CTD are replaced by hydrophobic Ile557 and negatively 
charged Glu617 in LGP2 CTD (Figure 3.9). These structural differences resulted in the 
dramatically different mode of non-ppp dsRNA binding by RIG-I and LGP2 CTDs. 
The overall structures of RIG-I, LGP2 and MDA5 CTDs are highly conserved 
(r.m.s.d. 1.5 Å) (Figure 1.3 and 3.8). The largest structural differences occur at the N-
terminal or C-terminal regions, which are quite flexible. The loops (loop5-6) connecting 
strands β5 and β6 also show high degree of flexibility. The conformation of this loop 
may determine how the RLRs recognize the exposed base pair at the termini of the 
dsRNA and likely influence the orientation of the RNA bound to the RLRs. Whether 
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MDA5 CTD uses a similar binding surface as RIG-I and LGP2 to bind blunt-ended 
dsRNA needs to be explored. 
 
 
 
 
 
 
 
Figure 3.8 Superposition of RIG-I CTD bound to the blunt-ended dsRNA with and 
without 5'-ppp, and LGP2 CTD bound to blunt-ended non-ppp dsRNA. 
The RIG-I CTD bound non-ppp dsRNA is shown by the blue ribbons, while the 5'-ppp 
dsRNA is orange. A 14-bp dsRNA (magenta ribbons) is superimposed on the 8-bp 
dsRNA in the LGP2 CTD:dsRNA complex structure to facilitate comparisons. 
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Figure 3.9 Electrostatics of the RNA-binding surfaces of the RLR CTDs. 
Positively charged surfaces are colored blue and negatively charged surfaces are red. 
The ppp-binding site of RIG-I CTD and corresponding regions of LGP2 and MDA5 are 
indicated by the green circles. Key residues involved in RNA-binding are labeled. 
Residues of RIG-I CTD interacting with the complementary strand of the dsRNA and 
corresponding residues in MDA5 and LGP2 CTDs are underlined. 
 
 
 
Mutations at the RNA binding surface affect RIG-I signaling 
As we discussed in Chapter II, all the three forms of RNA that bind to RIG-I 
CTD, including the blunt-ended dsRNA with and without 5'-ppp, are capable of 
activating RIG-I-dependent IFN-β reporter activities in HEK 293T cells (Figure 2.5).  
To test how mutations of key residues at the dsRNA binding surface affect RIG-I 
signaling, we generated five mutants in the context of full-length RIG-I and conducted 
IFN-β luciferase reporter gene assays (Figure 3.10). Expressions of wild-type and 
mutants of RIG-I in the transfected cells were confirmed by western blot (Figure 3.10, 
inset).  
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Figure 3.10 Mutations at the RNA binding surface affect RIG-I signaling. 
Effects of mutations at the RNA binding surface on IFN-β luciferase production were 
examined in cells transfected with a 27-bp blunt-ended non-ppp dsRNA (dsR27) and a 
24-bp dsRNA with 5'-ppp (3PdsR24). Expression of the wild-type and mutants of RIG-I 
in the transfected cells were confirmed by western blot (inset). 
 
 
 
Substitution of Arg811with glutamate abolished RIG-I signaling for both non-
ppp dsRNA and 5'-ppp dsRNA. Although the replacement of Lys812 by glutamate does 
not disrupt 5'-ppp dsRNA binding by RIG-I CTD, this mutation abolished signaling for 
both non-ppp dsRNA and 5'-ppp dsRNA. However, substitution of His871 with 
glutamate only reduced RIG-I signaling to 5'-ppp dsRNA by about 30%, but reduced 
signaling by non-ppp dsRNA by almost 50%. Consistent with results from RNA binding 
studies by RIG-I CTD mutants, replacement of the positively charged Arg811 with 
serine only slightly reduced RIG-I signaling by 5'-ppp dsRNA, but reduced the signaling 
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by non-ppp dsRNA by nearly 60%. In contrast, a serine substitution of the nearby 
Lys812 reduced signaling by non-ppp dsRNA and 5'-ppp dsRNA by about 80%.  
These results demonstrated that the two positively charged residues, Arg811 and 
Lys812, play critical roles in the recognition of non-ppp dsRNA by RIG-I. In addition, 
studies in Chapter II demonstrated that substitutions of any of the three positively 
charged residues, Lys888, Lys907, or Lys909, by glutamate also abolished RIG-I 
activation by both non-ppp dsRNA and 5'-ppp dsRNA (Figure 2.14). Moreover, 
hydrophobic interactions between the exposed base pair and RIG-I CTD are also 
important for the function of RIG-I; substitution of Phe853 by serine severely decreased 
RIG-I signaling in response to all the three forms of RNA (Figure 2.14). 
 
Discussion 
 To elucidate the structural features of viral RNA recognized by RIG-I, we 
expressed human RIG-I CTD, conducted RNA binding studies, and in here and Chapter 
II, determined the structures of RIG-I CTD bound to two different forms of RNA. These 
studies demonstrated that RIG-I CTD binds to 5'-ppp dsRNA or ssRNA as well as blunt-
ended dsRNA without 5'-ppp. The crystal structures of RIG-I CTD bound to the 14-bp 
blunt-ended dsRNA with and without 5'-ppp revealed that distinct but overlapping sets 
of residues contact the RNA. Mutations of key residues at the RNA binding surface 
differentially affect RNA binding and signaling by RIG-I. These results demonstrated 
that RIG-I CTD is a versatile RNA binding module capable of recognizing various RNA 
structures. The structures of RIG-I, LGP2 and MDA5 CTDs in isolation (60,72,73) and 
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the structures of RIG-I and LGP2 CTDs bound to RNA (74) allowed us to compare the 
RNA binding properties of the RLRs. 
A key question about the functions of the RLRs is what structural features of 
RNAs are recognized by these proteins. Biochemical, biophysical and cell-based 
approaches have been employed to elucidate the structures of RIG-I agonists. Several 
different techniques such as gel filtration chromatography, EMSA, and SPR have been 
used to study the RNA binding properties of RIG-I. These studies clearly showed that 
RIG-I CTD binds to 5'-ppp ssRNA or dsRNA, and blunt-ended dsRNA without 5'-ppp, 
but does not associate with ssRNA without ppp or dsDNA (74). Non-ppp dsRNA with 
5'-overhangs failed to bind RIG-I CTD, while dsRNA with 3'-overhangs retained some 
binding. In contrast, 5'-ppp dsRNA with either 3'- or 5'-overhangs still bind to RIG-I 
CTD (Chapter II). Although the RNA:DNA hybrid still binds to RIG-I CTD, it forms a 
1:1 instead of 1:2 complex with RIG-I CTD, suggesting that RIG-I CTD only recognizes 
one terminus of the hybrid with the RNA at the 5'-end. It is likely that RIG-I CTD does 
not bind the terminus of the hybrid with the DNA at the 5'-end. The affinity of 5'-ppp 
dsRNA (about 0.3 nM) for RIG-I CTD is higher than that of 5'-ppp ssRNA (about 5 nM) 
or non-ppp dsRNA (about 8 nM) (Chapter II). The affinities of RIG-I CTD for blunt-
ended dsRNA with and without 5'-ppp determined by isothermal titration calorimetry 
(ITC) are significantly lower than those determined by SPR (102). This is likely due to 
the techniques used and the salt concentrations in the samples. These studies 
demonstrated that blunt-ended non-ppp dsRNA and 5'-ppp dsRNA or ssRNA are all 
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ligands for RIG-I. Consistent with these results, all three forms of RNA activate RIG-I 
signaling in cells (90,101). 
The structures of RIG-I CTD bound to blunt-ended non-ppp dsRNA and 5'-ppp 
dsRNA provided insight into how RIG-I recognizes different forms of RNA. The two 
structures revealed that overlapping sets of residues are involved in the recognition of 
these two forms of RNA. The first four nucleotides at the 5'-end of 5'-ppp dsRNA make 
major contributions to 5'-ppp dsRNA binding. The ppp interacts with a cluster of 
positively-charged residues including Lys851, Lys858, Lys861, His847, and Lys888 
through multiple electrostatic interactions. The phosphodiester backbone makes 
additional interactions with the protein through a combination of electrostatic, hydrogen 
bonding and van der Waals interactions (Chapter II). Based on the structure of RIG-I 
CTD bound to 5'-ppp dsRNA, removal of the triphosphate should dramatically reduce 
dsRNA binding. However, RIG-I CTD can bind non-ppp dsRNA with nanomolar 
affinity. This is likely achieved through additional electrostatic interactions between the 
complementary strand and Arg811 and His871 in RIG-I CTD. Consistent with this 
observation, replacement of Arg811 with glutamate had severe effects on non-ppp 
dsRNA binding, but had a more modest effect on the binding of 5'-ppp dsRNA or 
ssRNA binding. Moreover, substitution of Arg811 with serine only reduced the signaling 
of non-ppp dsRNA. 
The 2'-hydroxyl of the ribose makes limited contributions to dsRNA binding. 
Only the 2'-hydroxyl of the 5'-terminal nucleotide is involved in direct and solvent 
mediated hydrogen bonds with RIG-I CTD. Modification of this hydroxyl by 
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methylation reduced the activity of 5'-ppp dsRNA in stimulating RIG-I signaling (102). 
It is likely that the steric hindrance caused by this modification reduced RNA binding. 
However, it is not clear why methylation of the 2'-hydroxyl of the second nucleotide also 
reduced RIG-I signaling (102), since this ribose makes no direct contact with RIG-I 
CTD.    
RIG-I CTD in complex with the blunt-ended non-ppp dsRNA crystallized in a 
different crystal form compared to the complex with corresponding 5'-ppp dsRNA. The 
non-ppp dsRNA complex did not crystallize under the conditions of the 5'-ppp dsRNA 
complex, and vice versa. The crystal packing for the two complexes is significantly 
different. This suggested that the two forms of dsRNA bind to RIG-I CTD in different 
orientations in solution. Although the ppp can be flexible in solution, it has to adopt a 
specific conformation to bind RIG-I effectively, so it is unlikely that 5'-ppp dsRNA will 
bind to RIG-I CTD in a similar orientation as the non-ppp dsRNA. This orientation may 
reduce the specific interactions between the ppp and RIG-I CTD. 
Crystal structures of RIG-I and LGP2 CTDs bound to dsRNA showed that the 
two proteins use similar binding surfaces to interact with RNA (Figure 3.8). It was 
suggested that a similar binding surface is also involved in RNA binding by MDA5 (73). 
Like RIG-I, LGP2 CTD also bind to the termini of the blunt-ended dsRNA (74). Some 
major differences in RNA binding by the three RLRs should be emphasized, however. 
Although LGP2 CTD binds to dsRNA with 3'-overhangs, it does not bind to dsRNA 
with 5'-overhangs (74). The RNA binding surfaces of the three proteins exhibit 
dramatically different electrostatic potentials (Figure 3.9) that should contribute to 
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different modes of protein:RNA interactions. The cluster of positively charged residues 
around Lys861 and Lys858 involved in 5'-ppp recognition is only observed at the RNA-
binding surface of RIG-I (Figure 3.9), explaining why both LGP2 and MDA5 CTDs 
have no preference for RNA ligands with 5'-ppp. The differences in surface electrostatics 
also explain why RIG-I and LGP2 CTDs bind to dsRNA in different ways. The 
differences should contribute to the function of these three innate immune receptors in 
the detection of viral infections. 
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CHAPTER IV 
INVESTIGATION OF RNA BINDING SURFACE OF MDA5* 
 
Background 
MDA5 is a second member of the RLR family proteins which is homologous to 
RIG-I. Both RIG-I and MDA5 encode tandem CARDs on their N-termini followed by a 
DExD/H box RNA helicase domain and a CTD which plays primary role in RNA 
recognition (49). Studies of RIG-I and MDA5 knockout mice demonstrated these two 
proteins detect different but overlapping sets of viruses, suggesting that they play 
different roles in antiviral immune responses (53,54,80). RIG-I discriminates between 
viral and host RNA through recognition of ssRNA with 5'-ppp group, a signature of viral 
RNA (19,61,62). In addition, chemically synthesized dsRNA and dsRNA derived from 
virus infected cells also activate RIG-I (41,52,53). Synthetic dsRNA mimics such as 
poly I:C or viral dsRNA of several kilobases in length activate MDA5 in cells (53,71). In 
contrast, short poly I:C of a few hundred base pairs in length only activates RIG-I (71).  
 
 
 
____________ 
*Part of this Chapter is reproduced with permission from “Structural basis of double-
stranded RNA recognition by the RIG-I like receptor MDA5” by Li X., Lu C., Stewart 
M., Xu H., Strong R.K., Igumenova T., and Li P. 2009. Archives of Biochemistry and 
Biophysics. 488, 23-33. Copyright (2009) by Elsevier. 
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It is likely that MDA5 is responsible for the detection of long dsRNA while RIG-I is 
activated by short dsRNA in addition to 5'-ppp ssRNA. The molecular mechanism of 
how viral RNA activates the RLRs is still largely unknown. 
The crystal structures of RIG-I CTD in isolation (72) and in complex with 
dsRNA with and without 5'-ppp (Chapter II and III) have been determined, providing 
insights into how RIG-I senses viral RNA. In addition, the crystal structures of LGP2 
CTD in isolation (60) and in complex with an 8-bp non-ppp dsRNA (74) were also 
solved. Strikingly, the LGP2 CTD/dsRNA complex structure revealed that LGP2 
specifically recognizes the blunt ends of dsRNA. LGP2 CTD exhibits a high degree of 
charge and shape complementarity to the first turn of dsRNA and interacts with the 
backbone of the dsRNA through extensive electrostatic interactions and hydrogen 
bonding. The exposed bases at the terminus of the dsRNA interact with LGP2 primarily 
through hydrophobic interactions. Similar to LGP2, the RIG-I CTD also recognizes 
blunt-ended dsRNA with and without 5'-ppp in addition to 5'-ppp ssRNA but does not 
bind to dsRNA with either 5'- or 3'-overhangs efficiently. Moreover, NF-κB and IFN-β 
reporter assays showed that RIG-I was activated by short dsRNA with blunt ends but not 
by dsRNA with 3'- or 5'-overhangs. Structures of RIG-I CTD complexes showed that 
RIG-I interacts with the termini of dsRNA with and without 5'-ppp in different 
orientations. However, it is not clear how MDA5 binds to RNA. 
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Figure 4.1 Crystal structure of human MDA5 CTD (PDB code 3GA3). 
(A) Ribbon representation of the structure of MDA5 CTD. The protein molecule is 
colored rainbow from blue at the N-terminus to red at the C-terminus. The zinc ion is 
shown by the gray sphere and side chains of four cysteine residues coordinating with the 
zinc ion are shown by stick models. 
(B) Surface electrostatic potential of MDA5 CTD. The orientation of MDA5 CTD is the 
same as in panel A with predicted binding surfaces facing the reader. Positively charged 
regions are colored blue, while negatively charged regions are red.  
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To elucidate the types of RNA recognized by MDA5, our lab have performed 
binding studies by gel filtration chromatography which showed that MDA5 CTD binds 
to blunt-ended dsRNA with and without 5'-ppp, and a short hairpin RNA containing only 
one blunt end, but not to 5'-ppp ssRNA, or dsRNA with either 5'- or 3'-overhangs (103). 
The stoichiometry of the dsRNA binding is estimated to be 1:1. Together with the 
equilibrium binding studies by SPR showing comparable affinities (Kd) of 5'-ppp dsRNA 
(5.7 ± 0.3 μM) and non-ppp dsRNA (2.8 ± 0.3 μM), these indicate that the 5'-ppp is not 
absolutely needed for dsRNA binding and MDA5 does not have a preference for the ppp 
group. The SPR sensorgrams showed characteristics of fast kinetics for the association 
and dissociation reactions, indicating that electrostatic interactions may have played a 
key role in the interactions between MDA5 CTD and the dsRNA (103).  
To understand the structural basis of dsRNA recognition by MDA5, our lab has 
determined a 1.45-Å resolution structure of human MDA5 CTD (residues 892-1017 with 
a C-terminal 6×His tag) (Figure 4.1A). The structure of MDA5 CTD revealed a highly 
conserved fold similar to the RIG-I and LGP2 CTDs (52,60,72). MDA5 CTD contains a 
four-stranded (β1, β2, β9 and β10) antiparallel β-sheet near its N-terminus and another 
four-stranded (β5, β6, β7 and β8) antiparallel β-sheet in the middle. The two β-sheets are 
connected by a β-hairpin formed by strands β3 and β4 and a short α-helix α1. Four 
conserved cysteine residues, Cys907, Cys910, Cys962, and Cys964, in the two loops 
connecting strands β1–β2 and β6–β7 make additional connection between the two β-
sheets by coordinating a zinc ion. The four cysteine residues are arranged tetrahedrally 
around the zinc ion and the distances between the sulfur atoms in the thiol groups and 
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zinc atom are about 2.35 Å. It is evident this zinc ion plays a crucial role in maintaining 
the overall fold of MDA5 CTD; mutations of these residues in RIG-I abrogate its 
response to RNA in vivo (72). Residues Tyr1015 to Glu1017 of MDA5 together with the 
6×His tag form a short helix α2. 
Although the amino acid sequence of MDA5 CTD is only 24.3% and 29.5% 
identical to the CTDs of RIG-I and LGP2, the structures of the three proteins are highly 
conserved, reflecting their conserved roles in dsRNA binding. The major structural 
differences between these proteins occur at the long loop (loop 5–6) connecting strands 
β5 and β6. The crystal structure of LGP2 CTD/dsRNA complex indicated that this loop 
is involved in the interactions between the blunt termini of dsRNA and LGP2 (74). 
Structural studies of RIG-I CTD by NMR spectroscopy and LGP2 CTD in isolation by 
crystallography indicated this loop is flexible (52,60). It is most likely that dsRNA 
binding induces a large conformational change in this loop to facilitate the interactions 
between the termini of dsRNA and RLRs.  
Based on the structures of RIG-I and LGP2 dsRNA complexes, we predict that 
the surface defined by the β-sheet containing β5 to β8, the β-hairpin, and the three loops 
connecting β5–β6, β8–β9, and β9 to the C-terminal helix in MDA5 is likely involved in 
dsRNA binding. Examination of this potential RNA binding surface showed that it is 
positively charged and exhibits a high degree of shape complementarity to the structure 
dsRNA (Fig. 4.1B), although it is different from that of RIG-I and LGP2 CTDs, 
reflecting a different role in viral RNA sensing. 
  
116 
Because we failed to cocrystallize MDA5 CTD together with dsRNA, in order to 
examine the interaction between MDA5 CTD and dsRNA, we would like to explore the 
binding surface by NMR spectroscopy in this study. 
 
Materials and methods 
Construction of MDA5 CTD expression plasmids by molecular cloning 
The cDNA of human MDA5 (IFIH1) was purchased from Open Biosystems 
(Thermo Scientific). The region encoding MDA5 CTD (residues 893-1017) was cloned 
into bacterial expression vector pET22b(+) (Novagen) between NdeI and XhoI 
restriction sites, in order to be expressed with an C-terminal 6×His tag. The C-terminal 
eight residues of MDA5 (residues 1018-1025) were excluded from the construct to 
prevent protein dimerization via cysteine residues 1018 and 1019. The PCR primers 
(IDT) used were: 
Forward primer 5'- TATATATACATATGGCCAAGCATTACAAGAATAAC -3'  
Reverse primer 5'- TATATACTCGAGATCCTCATCACTAAATAAAC -3' 
The cloning methods were described in Chapter II. The cloned DNA sequences 
were confirmed by plasmid DNA sequencing (Institute of plant genomics and 
biotechnology, Texas A&M University). 
 
Protein expression and purification 
MDA5 CTD was expressed in E. coli strain BL21(DE3) by induction at OD600 = 
0.6-0.8 with 0.1 mM IPTG overnight at 15°C. Uniform 13C and 15N labeling of MDA5 
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CTD was accomplished by growing E. Coli cells in minimal media M9 supplemented 
with 2 g/L of [13C-6]-D-glucose and 1 g/L of 15NH4Cl (Cambridge Isotopes). The protein 
was purified by Ni2+ affinity chromatography followed by gel filtration chromatography 
following the same protocol for RIG-I CTD purification described in Chapter II. 
 
NMR spectroscopy 
MDA5 CTD samples for NMR experiments were prepared in 20 mM Tris-HCl 
pH 6.8, 150 mM NaCl, and 5 mM DTT. 8% D2O was added to each sample for NMR 
lock. All NMR experiments were carried out at 25°C on Varian Inova spectrometers 
operating at 1H Larmor frequencies of 500 and 600 MHz with help from our 
collaborators at Texas A&M University (Dr. Tatyana Igumenova group, Department of 
Biochemistry and Biophysics). Sequential assignments of the backbone 1H, 13Cα, 13Cβ, 
and 15N were obtained using gradient-enhanced CBCA(CO)NH and HNCACB 
experiments (104) with samples at 1 mM. NMR titration of MDA5 CTD with a 10-bp 
dsRNA was carried out at 500 MHz. The protein concentration was maintained at 100 
μM, while the concentration of a 10-bp dsRNA (with palindromic sequence 5'- 
GGCGCGCGCC -3') was adjusted to 12, 30, 60, 120, and 240 μM in a set of NMR 
samples. The binding of 10-bp dsRNA to MDA5 CTD was monitored using two-
dimensional 1H–15N HSQC spectra that correlate amide proton and nitrogen chemical 
shifts of the protein. NMR data were processed with nmrPipe (105) and assigned with 
Sparky 3 (http://www.cgl.ucsf.edu/home/sparky). 
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Results 
1H-15N HSQC spectrum of MDA5 CTD 
Our laboratory successfully determined the crystal structures of MDA5 CTD 
alone, and dsRNA complexes of RIG-I and LGP2 CTDs. Clearly, a structural 
comparison of the RNA complexes of RLRs would be highly informative. However, 
despite extensive effort, MDA5 CTD complexes resisted crystallization. As an 
alternative to X-ray crystallography, analysis by NMR spectroscopy in combination with 
molecular modeling can provide structural information, to allow comparison of the RLR 
CTDs interactions with viral RNA.  
1H-15N HSQC experiment (106) is probably the most frequently recorded 
experiment in protein NMR spectroscopy. The resulting spectrum is two-dimensional 
with one axis for 1H and the other for the heteronucleus 15N. Each residue of the protein 
(except proline) has an amide proton attached to the nitrogen in the peptide bond. Each 
N-H pair gives an individual cross peak because of the different chemical environments. 
If the protein is folded, the peaks are usually well dispersed, and most of the individual 
peaks can be distinguished. The number of peaks in the spectrum should generally match 
the number of residues, with the exception of proline which lacks an amide proton hence 
has no cross-peaks, while residues like arginine and lysine would have additional peaks 
because of their side chains with nitrogen-bound protons.  
Excellent chemical shift dispersion of the ligand-free MDA5 CTD 1H -15N 
HSQC spectrum (Figure 4.2) has made it possible to identify the dsRNA binding surface 
of MDA5 CTD. Theoretically there are 160 N-H groups in the His-tagged MDA5 CTD 
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protein which has 133 residues. On the HSQC spectrum, there are about 142 individual 
peaks. It sounds a good alternative method to study the binding surface of MDA5 CTD. 
Each of the residue in MDA5 CTD was assigned with one cross peak in the 
HSQC spectrum (Figure 4.2) by sequential assignments of the backbone 1H, 13Cα, 13Cβ, 
and 15N using gradient-enhanced CBCA(CO)NH and HNCACB experiments (104). 
 
Identification of the dsRNA binding surface of MDA5 CTD 
In order to identify the residues involved in dsRNA binding surface of MDA5 
CTD by NMR spectroscopy, we performed a RNA titration study by collecting HSQC 
spectra for a series of MDA5 CTD sample mixtures with increasing dsRNA 
concentrations. By overlaying each of the HSQC spectra together (Figure 4.3), we can 
notice the cross-peaks with chemical shift changes (e.g. decrease in intensity) which 
indicate residues involved in or at least perturbed by the interaction between MDA5 
CTD and the dsRNA. 
  
120 
 
Figure 4.2 2D 1H-15N HSQC spectrum of MDA5 CTD with assigned cross-peak identities.  
Inset shows an enlarged region as an example. 
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Figure 4.3 Overlay of 1H-15N HSQC spectra of MDA5 CTD titrated with dsRNA.  
The spectra of 100 μM MDA5 CTD with 10-bp dsRNA at concentrations of 0 μM, 12 μM, 30μM, 60 μM, 120 μM, and 240 
μM are shown in blue, green, cyan, yellow, red, and maroon, respectively. 
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Figure 4.4 1H-15N HSQC spectra of 100 μMDA5 CTD in the presence of 0 μM (black), 
12 μM (red), and 30 μM (green) dsRNA. 
Cross-peaks whose intensity decreased in response to adding of 12 μM dsRNA are 
labeled. 
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For the majority of residues that are involved in or perturbed by protein-dsRNA 
interaction, the kinetics of dsRNA binding to MDA5 CTD falls into an intermediate 
exchange regime on the NMR chemical shift timescale, resulting in broadening and 
gradual disappearance of cross-peaks with increasing ligand concentration. Even at low 
concentration of the dsRNA, 12 μM, the effect of ligand binding was noticeable for the 
21 residues whose cross-peaks are labeled in the NMR spectrum (Fig. 4.4). At each 
concentration of dsRNA up to 60 μM, we identified the protein residues whose cross-
peaks disappeared, or significantly changed their intensity and/or chemical shift 
compared to the ligand-free protein. These residues are mapped onto the crystal structure 
of MDA5 CTD (Figure 4.5). 
Most of the residues with reduced intensity in the spectra are located on the 
hairpin containing strands β3 and β4, the loop connecting β5 and β6, the strands β7 and 
β8, the loop connecting β8 and β9, and the loop connecting strands β10 to the C-terminal 
helix (Figure 4.5 and 4.6). Obviously, these residues are mapped on the surface of 
MDA5 that corresponds to the dsRNA binding surfaces of RIG-I and LGP2 CTDs 
(Figure 4.6). These results indicate that all the three RLRs use a highly conserved 
positively charged surface to bind dsRNA. Since the overall structure of MDA5 CTD is 
very similar to LGP2 CTD, it is likely MDA5 binds to the blunt ends of dsRNA in a 
similar way as LGP2. Only a few residues on the opposite surface of MDA5 CTD 
showed significant changes in intensity or chemical shift upon dsRNA binding (Figure 
4.5). In addition, a number of residues near the dsRNA binding surface but do not 
contact the dsRNA directly also showed reduced intensity in the presence of dsRNA, 
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indicating a global conformational adjustment of MDA5 CTD may be involved in 
dsRNA binding. 
 
 
 
 
 
 
Figure 4.5 Mapping of amino acid residues involved in dsRNA binding identified by 
NMR spectroscopy onto the crystal structure of MDA5 CTD. 
Residues involved in dsRNA binding at RNA concentrations of 12 μM, 30 μM, and 60 
μM are colored orange, teal, and chocolate, respectively. 
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Figure 4.6 Structure-based sequence alignment of human MDA5, RIG-I, and LGP2 
CTDs. 
Conserved residues in the three proteins are shown in red. Residues of MDA5 not 
included in the protein construct are shown in light blue. Secondary structural elements 
of MDA5 CTD are shown under the aligned sequences. Residues of MDA5 involved in 
dsRNA binding at concentrations of 12 μM, 30 μM, and 60 μM are highlighted in yellow, 
cyan, and chocolate, respectively. NMR titration of RIG-I CTD identified overlapping 
sets of residues involved in dsRNA and 5'-ppp ssRNA (52). Residues of RIG-I CTD 
involved in dsRNA are highlighted in yellow; residues involved in 5'-ppp ssRNA 
recognition in addition to those residues that are involved in dsRNA binding are 
highlighted in olive. Residues of LGP2 CTD involved in dsRNA binding observed in the 
crystal structure of the LGP2 CTD/dsRNA complex (74) are highlighted in green. 
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HSQC spectra of MDA5 CTD-dsRNA complexes collected at 120 μM and 240 
μM dsRNA concentrations are virtually indistinguishable (Figure 4.3), indicating full 
saturation of protein with ligand. Even at saturating concentrations of dsRNA we 
observed significant line-broadening of NMR cross-peaks that cannot be fully explained 
by an increase in molecular weight due to the protein-dsRNA complex formation. One 
plausible explanation is the formation of a 2:1 complex between MDA5 CTD and the 
dsRNA at higher concentrations, which increases the molecular weight of the complex 
significantly. 
 
Discussion 
RNA binding studies by gel filtration chromatography and SPR demonstrated 
that MDA5 CTD only binds dsRNA with blunt ends, but does not associate with dsRNA 
with either 5'- or 3'-overhangs. These confirmed previous findings that MDA5 is a 
sensor of dsRNA. Similar preferences of blunt-ended dsRNA were also observed for the 
LGP2 and RIG-I CTDs, indicating the blunt end of dsRNA is most likely a common 
structural motif recognized by the RLRs (74). However, unlike RIG-I, MDA5 and LGP2 
have no preference for the 5'-ppp group. The CTD of MDA5 exhibits significantly lower 
affinities for dsRNA (Kd ~ 3 μM) compared to the CTD of LGP2 (Kd ~ 100 nM) (74) 
and RIG-I (Kd ~ 4.6 nM), suggesting that MDA5 needs higher concentrations of ligands 
for activation. Since MDA5 CTD has lower affinities for dsRNA, it forms a 1:1 complex 
with the 10-bp dsRNA at low concentration and a mixture of 1:1 and 2:1 complexes at 
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higher concentration, making the MDA5/dsRNA complex heterogeneous and resistant to 
crystallization. 
To elucidate the structural basis of dsRNA recognition by MDA5, our laboratory 
has determined the high-resolution structure of MDA5 CTD by X-ray crystallography 
and in this study mapped its binding surface for dsRNA by NMR spectroscopy. The 
structure of MDA5 CTD revealed a highly conserved fold similar to RIG-I and LGP2 
CTDs. All the three proteins show a high degree of shape and charge complementarity 
with the first turn of blunt-ended dsRNA. Consistent with this, NMR titration of MDA5 
CTD with dsRNA indicated that a conserved positively charged surface is involved in 
dsRNA binding. Structural studies of RIG-I and LGP2 CTDs in complex with dsRNA 
by X-ray crystallography indicated that a similar binding surface is involved in dsRNA 
and ssRNA binding by RIG-I and dsRNA binding by LGP2.  
Based on the RNA binding surface mapped by NMR spectroscopy, and the 
structural comparison of MDA5 CTD with the RIG-I and LGP2 CTD/dsRNA 
complexes, seven mutants of MDA5 CTD were generated and their binding properties 
were analyzed by gel filtration chromatography (103). Mutation of the positively 
charged residues Lys950, Lys983, and Lys1002 to negatively charged glutamate 
abolished dsRNA binding. Consistently, mutation of lysine residues in RIG-I and LGP2 
CTDs corresponding to Lys983 and Lys1002 in MDA5 also disrupted RNA binding by 
RIG-I and LGP2 (52,74), demonstrating their pivotal roles in dsRNA recognition by 
RLRs. In addition, mutation of the conserved His927 that is involved in the formation of 
a network of hydrogen bonds in the RIG-I and LGP2 CTD complexes also disrupted 
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dsRNA binding by MDA5 CTD. However, mutation of Glu924 or Leu947 which may 
interact with dsRNA by hydrogen bond and hydrophobic interactions, did not abrogate 
dsRNA binding by MDA5 CTD, suggesting these two residues might contribute to 
dsRNA binding but do not play dominant roles. As a control, mutation of Arg942, a 
residue that is not on the predicted dsRNA binding surface of MDA5, did not affect 
dsRNA binding. These mutagenesis studies demonstrated that similar to RIG-I and 
LGP2, a highly conserved positively charged surface is involved in dsRNA binding by 
MDA5 CTD, and electrostatic interactions play primary roles.  
 
 
 
Figure 4.7 Structural model of MDA5 CTD bound to a 12-bp dsRNA. 
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Based on the above NMR and mutagenesis studies and other RLR CTD complex 
structures, a structural model of MDA5 CTD bound to a 12-bp dsRNA was generated 
(Figure 4.7) (103), which suggested that MDA5 may recognize the blunt end of dsRNA 
and bind to the first turn of it in a similar manner as its homolog LGP2. 
Since several mutants of MDA5 with abolished dsRNA binding were identified, 
it would be interesting to test whether these mutants of MDA5 still stimulate type I IFN 
induction in virus infected cells. These studies will provide insight into whether the 
dsRNA binding is needed for MDA5 signaling. Since the coexpression of LGP2, which 
exhibits much higher affinities for dsRNA than MDA5, stimulated rather than 
suppressed the activation of MDA5 (60), the roles of dsRNA binding in MDA5 
activation need to be reconsidered. It is also possible that dsRNA binding is not required 
for the regulation of MDA5 by LGP2. Previous studies from two independent groups 
already showed that mutants of LGP2 with abolished RNA binding still suppress the 
activation of RIG-I (74,89). 
RNA binding studies clearly showed MDA5 CTD also binds to short dsRNA of 8 
to 24 bp in length just like the CTDs of LGP2 and RIG-I. Since the affinity of MDA5 
CTD for blunt-ended dsRNA is only about 3 μM, it is difficult to understand why full-
length MDA5 prefers long dsRNA instead of short dsRNA as ligands, since the 
concentration of the blunt ends, the structural motif of dsRNA recognized by MDA5, 
would be very low for a given amount of long dsRNA. For example, a solution of a 2-kb 
dsRNA at 3 μM concentration corresponds to a solution of 20-bp dsRNA at 300 μM 
concentration with the same amount of RNA. On the other hand, the maximum length of 
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dsRNA that can be covered by a full-length MDA5 molecule is likely about 30 bp 
assuming the maximum dimension of the molecule is about 100 Å as observed in the 
electron microscopy structure of full-length LGP2 and RIG-I (99,100). Moreover, 
previous studies demonstrated that 24-bp but not 19-bp dsRNA stimulates the activation 
of RIG-I, indicating that the 24-bp dsRNA is long enough to form an active complex 
with full-length RIG-I (74). The activation of antiviral ribonuclease, RNase L, by 2',5'-
linked oligoadenylate (2-5A) produces small RNA cleavage products that initiate IFN 
production (30). This is likely a mechanism to generate a large amount of short dsRNA 
to simulate the activation of the RLRs. However, it is not clear whether the products of 
RNase L serve as ligands for MDA5. The mechanism of how MDA5 is selectively 
activated by long dsRNA and poly I:C needs further investigation. 
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CHAPTER V 
STRUCTURAL STUDIES OF RIG-I ACTIVATION  
 
Background 
The molecular mechanism of how viral RNA activates the RIG-I is still largely 
unknown. It was suggested that under resting condition RIG-I is in a suppressed 
conformation and RNA binding induces a major conformational change which requires 
ATP hydrolysis, exposing the CARDs for the recruitment of the mitochondria bound 
adaptor protein IPS-1, which relays the signal to downstream proteins (49,51). 
Stimulation of the RIG-I ultimately leads to the activation of transcription factors IRF3, 
IRF7, and NF-κB that regulate the induction of type I IFNs and proinflammatory 
cytokines (21,70,80). 
To understand those mechanistic questions concerning RIG-I activation pathway, 
including the nature of the conformational changes, the role of ATP hydrolysis, and the 
dimerization or oligomerization state associated with viral RNA binding, it would be 
necessary to obtain the structural information for different states or conformations of 
RIG-I. Although the crystal structures of RIG-I CTD complexes with different dsRNA 
have been determined, the overall structure of full-length RIG-I or structures of other 
domains are still unknown. In this study, we would like to further investigate into the 
mechanism for RIG-I activation by crystallizing RIG-I HD-CTD, which contains both 
the helicase domain and the CTD, in complex with dsRNA. 
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RLRs are members of the large SF2 helicases family and each contain a 
DExD/H-box helicase domain. The RLRs share a conserved catalytic core consisting of 
two RecA-like domains similar to SF1 and SF2 helicases. Eight conserved helicase 
domain sequence motifs cluster into the two RecA subdomains which forms an active 
site for ATP binding and hydrolysis (107). The name DExD/H box refers to the 
signature sequence, which is “DECH” for the RLRs, in motif II which is also known as 
the Walker B motif that is crucial for the hydrolysis of ATP (108). Both RIG-I and 
MDA5 strictly require RNA ligand stimulation for the ATPase activity, while LGP2 
exhibits a low level of basal ATP hydrolysis in the absence of RNA (89). However, 
though all three RLRs are able to hydrolyze ATP, only RIG-I has been reported to have 
ATP-dependent RNA unwinding activity to date (52,66). Interestingly, the helicase 
activity of RIG-I appears to be reversely correlated with its antiviral signaling capacity 
stimulated by specific RNA ligands (52). Questions remain about the roles of RNA 
helicase activity in RLRs activation and signaling. Therefore a structural study of RIG-I 
HD-CTD in complex with dsRNA would provide insights into RNA induced RIG-I 
activation. 
Epigallocatechin-3-gallate (EGCG) is a green tea catechin that is recently 
identified in a small molecule screen as a RIG-I regulator that can bind to RIG-I and 
modulate its signaling (109). It inhibits RIG-I signaling in cell-based reporter gene 
assays. EGCG also inhibits the RNA-dependent ATPase activity of recombinant RIG-I 
in biochemical assays, however it does not compete with RIG-I interaction with RNA or 
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with ATP. It would be intriguing to elucidate the structural mechanism of this inhibition, 
which possibly involves the helicase domain, by crystallography study.   
 
Materials and methods 
Cloning and protein expression of RIG-I HD-CTD 
Human RIG-I HD-CTD (residues 232-925) was cloned into the insect cell 
expression vector pAcGHLT-2 (BD Biosciences), which contains N-terminal GST-tag 
and 6×His-tag followed by a thrombin-cleavage site. Using such a construction, after 
thrombin cleavage, the peptide GSPGLDGSC will remain at the N-terminal end of the 
protein, corresponding to a molecular weight of 80196.5 Da for the isolated module. The 
target gene was PCR amplified and insert into the vector using NdeI and NotI restriction 
enzymes. The DNA sequence was verified by plasmid sequencing. The PCR primers 
(IDT) used were: 
Forward primer 5'- TATATATACATATGCGTGTCTGATACAAAC -3' 
Reverse primer 5'- TATATAGCGGCCGCTCATTTGGACATTTCTGCTGG -3' 
The 6×His-GST-tagged RIG-I HD-CTD was expressed in insect cells Sf9 
(Spodoptera frugiperda) using baculovirus expression system. Recombinant baculovirus 
was generated in Sf9 cells using BaculoGold linearized baculovirus DNA (BD 
Biosciences) and the recombinant pAcGHLT-2 plasmid according to the manufacturer’s 
protocol. Sf9 cells were maintained in suspension culture in HyClone SFX-serum free 
insect cell culture medium (Thermo Scientific) at 27°C. For large-scale protein 
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expression, 2 L of Sf9 cell culture at a density of 2.5 × 106 ml-1 were infected with 120 
ml recombinant virus and incubated at 120 rpm at 27°C for 58 h.  
To be expressed in bacterial system, RIG-I HD-CTD was also cloned into a 
pET28a(+) derived vector with an N-terminal SUMO tag. The target gene was PCR 
amplified and insert into the vector using SalI and NotI restriction enzymes, to be 
expressed with an N-terminal 6×His-SUMO fusion. The linker region between SUMO 
and HD-CTD were then removed by mutagenesis PCR. Using such a construction, the 
expressed HD-CTD protein will have no extra residues before its N-terminal after 
treated with SUMO protease. The PCR primers (IDT) used in this study were: 
For cloning PCR 
Forward primer 5'- TATATAGTCGACAAGTGTCTGATACAAACTTGTAC -3' 
Reverse primer 5'- TATATAGCGGCCGCTCATTTGGACATTTCTGCTGG -3' 
For mutagenesis PCR 
Forward primer 5'- GAACAGATTGGTGGATCCGTGTCTGATACAAACTTG -3' 
Reverse primer 5'- CAAGTTTGTATCAGACACGGATCCACCAATCTGTTC-3' 
The protein was expressed in E. coli BL21(DE3) cells. The culture was grown at 
37°C in LB medium with 50 μg/ml kanamycin to an OD600 of 0.6-0.8. ZnSO4 (at 0.2 
mM) was added to the medium because RIG-I HD-CTD is a Zinc binding protein. The 
culture was then induced with 0.5 mM IPTG at 15°C and grown overnight. 
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Purification and crystallization of RIG-I HD-CTD in complex with a 24-bp dsRNA 
Sf9 insect cells expressing human RIG-I HD-CTD were harvested 58 h post-
infection by centrifuging at 2000 rpm for 5 min. The cell pellets were resuspended in 
150 ml Lysis Buffer [200 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% (v/v) NP40, and 
1mM phenylmethylsulfonyl fluoride (PMSF)] and lysed at 4°C for 2 h on a rolling 
shaker. Cellular debris was sedimented by centrifugation of the lysate at 16000 rpm for 
30 min. The supernatant was incubated at 4°C for 2 h with 6 ml Ni-NTA superflow 
(Qiagen) on a rolling shaker. The slurry was loaded by gravity into an empty column and 
washed with about 200 ml of the Washing Buffer, prior to elution with about 25 ml 
Elution Buffer. After eluted from the Ni-NTA beads, 5 mM DTT was added to the 
protein immediately.  
The 24-bp non-ppp dsRNA (IDT) used to form complex with RIG-I HD-CTD 
was generated by annealing of two complementary ssRNAs (5'- GCGCACGUGCGC 
GCGCGUGCACGC and 5'- GCGUGCACGCGCGCGCACGUGCGC). The purified 
RIG-I HD-CTD protein was mixed with the 24-bp dsRNA at a molar ratio of about 3:1. 
The mixture was stored at 4°C for 2 days to form stable 2:1 (protein:RNA) complex 
before thrombin cleavage to remove the 6×His-GST-tag. The complex was then purified 
by gel filtration chromatography for twice on a Superdex 200 (1.6 × 60) column (GE 
Healthcare) in the Tris-NaCl buffer. The purified complex sample was concentrated to 
about 5 mg/ml using 30kDa cutoff Amicon Ultra centrifugal filter units (Millipore). 
All crystallization experiments employed the hanging-drop vapour-diffusion 
method and were conducted at 4°C, using 24-well plates (Hampton Research). Initial 
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screening was performed against 336 crystallization conditions using Index, Crystal 
Screen (I & II), Natrix, and PEG/Ion (I & II) kits (Hampton Research). Drops were 
prepared by mixing 2 μl reservoir solution with 2 μl protein solution (5 mg/ml HD-
CTD/RNA complex in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM DTT, and 1 mM 
ATP) and were equilibrated by vapour diffusion against 500 μl reservoir solution. 
Several initial hits were obtained with small needle-like crystals within a week. After 
extensive optimization trials, plate-like rod crystals with maximum dimensions of 300 × 
100 × 20 μm3 were obtained in 0.2 M MgCl2 and 12% (w/v) PEG 3350 within two 
weeks. 
Crystals were transferred into a cryoprotectant solution composed of reservoir 
solution with 30% (w/v) sucrose and then flash-frozen in liquid N2. Diffraction data 
were collected at Stanford Synchrochon Radiation Lightsource (SLAC National 
Accelerator Laboratory, Menlo Park, CA, USA). Data were indexed, integrated and 
scaled using HKL-2000 (92). 
 
Purification and crystallization of RIG-I HD-CTD in complex with a 14-bp dsRNA 
E. coli BL21(DE3) cells expressing human RIG-I HD-CTD were harvested by 
centrifugation at 4°C, 6000 rpm for 10 min. Cell pellets were lysed and purified by 
nickel affinity chromatography on a His-Select nickel affinity resin (Sigma-Aldrich) 
column following the same protocol for RIG-I CTD purification described in Chapter II. 
The 14-bp 5'-ppp dsRNA used to form complex with RIG-I HD-CTD was 
generated by annealing of a T7 RNA polymerase in vitro transcribed ssRNA with 
  
137 
palindromic sequence 5'- GGCGCGCGCGCGCC). The purified RIG-I HD-CTD protein 
was mixed with the 14-bp dsRNA at a molar ratio of about 1:1.5 to form a 1:1 
(protein:RNA) complex. The 6×His-SUMO-tag was removed by SUMO protease 
treatment. The complex was then purified by gel filtration chromatography on a 
Superdex200 (1.6 × 60) column (GE Healthcare) eluted with the Tris-NaCl buffer. The 
purified complex sample was concentrated to about 10-15 mg/ml using 10-kDa cutoff 
Amicon Ultra centrifugal filter units (Millipore). 
The HD-CTD/14-bp dsRNA complex (in 20 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 5 mM DTT, 5 mM MgCl2) in the presence of 1 mM ATP or inhibitor EGCG 
(Sigma Aldrich) was crystallized by hanging-drop vapour-diffusion method at 16°C in 
17-20% (w/v) PEG 3350, 0.2 M NaSCN, and 6% trifluoroethanol. Crystals appear in 2-3 
days and grow into large hexagonal rods in 1-2 weeks. 
 
Results 
Purification and crystallization of RIG-I HD-CTD in complex with a 24-bp dsRNA 
We have successfully cloned the human RIG-I HD-CTD gene and generated 
recombinant baculovirus for the overexpression of the protein in eukaryotic Sf9 cells for 
proper protein folding. The protein/RNA complex sample for crystallization was purified 
to homogeneity according to the purification protocols outlined in the materials and 
methods section. RIG-I HD-CTD with N-terminal 6×His-GST fusion was first purified 
using Ni-affinity and immediately mixed with the 24-bp dsRNA to form stable complex 
before the GST-tag was removed, otherwise the protein tends to precipitate during buffer 
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exchange and thrombin cleavage. The complex was then purified by gel filtration 
chromatography. To completely separate the 2:1 complex from extra protein and uncut 
GST-tagged protein, the complex was purified two times using a Superdex 200 gel 
filtration column and only the best fractions were collected for crystallization 
experiments. Figure 5.1 represents a typical gel filtration purification profile. The purity 
of the protein was verified on a 10% SDS-PAGE gel showing a single band at 80 kDa 
(Figure 5.2). 
This complex sample was used to set up crystallization screens using over 300 
different conditions. Small crystals in the forms of fine needles or needle clusters appear 
after about one week in several conditions. Several rounds of optimization were carried 
out with different precipitant concentrations and pH, however the crystals were not 
improved much. 
Next we tried to add 2 mM of ATP to our complex sample mixture for 
crystallization. Better crystals appear in the shape of thin plates instead of fine needles, 
in optimization conditions containing 0.2 M MgCl2, and 10-13% PEG 3350. This 
indicated that the ATP hydrolysis by the helicase domain may be required for a 
conformational change of the RIG-I HD-CTD which stabilizes the complex and make it 
favorable for crystallization. Based on this, we also tried to use ADP, the 
nonhydrolyzable ATP analog AMP-PNP, or the transition state analog ADP-AlF3. 
However, none of them resulted in better crystals. 
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Figure 5.1 Gel filtration chromatograms of RIG-I HD-CTD complex purification. 
The purification profile of RIG-I HD-CTD in complex with the 24-bp dsRNA on a 
Superdex 200 column shows the absorbance peak at 280 nm. The first round of 
purification is shown in blue chromatogram and the second shown in red. 
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Figure 5.2 SDS-PAGE analysis of purified RIG-I HD-CTD complex. 
RIG-I HD-CTD together with Precision Plus Protein Dual Color Standards (25-250 kDa, 
Bio-Rad) were shown on a 10% SDS-PAGE gel stained with Coomassie Blue. 
 
 
 
After further optimization trials by changing the concentrations of protein 
complex, ATP, salt MgCl2, and precipitant PEG 3350, plate-like crystals with maximum 
dimensions of 300 × 100 × 20 μm3 were obtained using 5 mg/ml in the presence of 1 
mM ATP, in 0.2 M MgCl2 and 12% (w/v) PEG 3350. The crystals were harvested and 
subjected to X-ray diffraction studies using synchrochon beamline. The crystals 
diffracted to 3.5-Å resolution. However, the diffraction data showed that the crystals 
were not single and cannot be used for structure determination. Preliminary analysis of 
the diffraction data indicated that the crystals belong to the space group P222, with unit-
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cell parameters a = 101.9 Å, b = 247.99 Å, c = 255.44 Å. Better crystals need to be 
obtained from further optimizations in the future. 
 
Purification and crystallization of RIG-I HD-CTD in complex with a 14-bp dsRNA 
While we were still working on the optimization of RIG-I HD-CTD complex 
crystals, recently, two groups have independently determined the crystal structures of 
RIG-I HD-CTD in complex with a 10- and a 14-bp dsRNA without 5'-ppp (110,111). 
Their structures provided insights into the roles of the helicase domain in RNA binding 
and RIG-I conformational change. Based on their methods, we generated a similar 
construct of RIG-I HD-CTD as a 6×His-SUMO-tagged protein which can be expressed 
in bacterial system, and successfully reproduced the complex crystal of RIG-I HD-CTD 
bound to the 14-bp dsRNA in 0.2 M NaSCN, 20% PEG 3350, and 3% trifluoroethanol.  
Because the 10- and 14-bp dsRNA used by these two groups both lack the 5'-ppp 
preferred for signaling, it would still be interesting to see a structure of the HD-CTD in 
complex with a 5'-ppp dsRNA. Therefore we generated a 14-bp 5'-ppp dsRNA with GC-
rich sequence by in vitro transcription using T7 RNA polymerase, and use it for 
cocrystallization. E. coli expressed RIG-I HD-CTD was purified by nickel affinity 
purification followed by complexes formation, SUMO-protease treatment, and gel 
filtration chromatography purification, similar to the steps that were used to process the 
HD-CTD/24bp dsRNA complex. Crystallization trials were set up using conditions 
around the one described above for the 14-bp non-ppp dsRNA. Hexagonal rod-like 
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crystals appeared in 0.2 M NaSCN, 17-19% PEG 3350, and 6% trifluoroethanol. Further 
optimizations of the crystals are needed as a future work. 
EGCG is an inhibitor of RIG-I sinaling and ATPase activities without competing 
with RNA or ATP binding. Therefore it would be interesting to see where it binds to 
RIG-I and how it affects RIG-I structural conformation. We crystallize the RIG-I HD-
CTD/14bp dsRNA complex in presence of different amount of EGCG with or without 
ATP, in conditions containing 0.2 M NaSCN, 15-25% PEG 3350, and 6% 
trifluoroethanol. The samples crystallized in similar shape as the crystals without 
inhibitor, but appeared to be thinner and longer. Further optimizations of the crystals are 
needed in the future work. 
 
Discussion 
In this study, we successfully developed an approach to purify the RIG-I HD-
CTD and dsRNA complexes to high quality, and obtained their crystals, although we did 
not manage to collect diffraction data which is good enough for structure determination.  
Recently, four groups have made breakthroughs in the studies of RIG-I activation 
mechanisms. Two groups determined the crystal structures of human RIG-I HD-CTD 
(RIG-I ΔCARDs) complexes, one with a 10-bp dsRNA and the other with a 14-bp 
dsRNA, at 2.5 Å and 2.9 Å resolutions, respectively (110,111). Another group presented 
the crystal structure of mouse RIG-I helicase domain (SF2 ATPase domain) in complex 
with the nucleotide analogue AMP-PNP, at 2.2 Å resolution (112). A fourth group 
reported the crystal structures of duck RIG-I constructs including the helicase domain 
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alone (3 Å) and in ternary complex with a non-ppp 19-bp dsRNA and an ATP analog 
AMP-PNP (4.2 Å) or ADP-AlF3 (3.7 Å), the CARDs-helicase (ΔCTD, 3.4 Å), and full-
length duck RIG-I (3.7 Å) (113). These recently published structures provide detailed 
information for understanding the mechanism of RIG-I activation by viral RNA. 
Although using different fragments and origins of RIG-I, all four groups 
determined the crystal structures of the helicase domain, which contains two RecA-like 
domains (HEL1 and HEL2) together with a unique insertion domain in HEL2 (HEL2i) 
(Figure 5.3A). Intriguingly, there is a V-shaped structure which is composed of two long 
α helices, named the “pincer motif” (110) or “bridge” (113), that extends from HEL2, 
folds back to interact with HEL1, and then connects to the CTD (Figure 5.3B).  
RIG-I completely surrounds the dsRNA molecule and encloses it in a ring 
structure, covering a region of 9–10 bp along the dsRNA (Figure 5.3). HEL1 faces the 
minor groove of the dsRNA and interacts with the RNA backbone of both strands, and 
the HEL2i domain contributes significantly to RNA binding. However, in the structure 
of RIG-I HD-CTD in complex with 10-bp dsRNA, the HEL2 domain is not in close 
contact with the RNA(Figure 5.3) (110), whereas in the structure of HD-CTD in 
complex with 14-bp dsRNA in the presence of an ATP analog ADP-BeF3, the HEL2 
domain directly interacts with the dsRNA (111), presumably because of the ATP-
dependent conformational change coordinated by the pincer motif which functions like 
“the camshaft in an engine” (110). 
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Figure 5.3 The RIG-I HD-CTD (ΔCARDs) dsRNA complex (110)*. 
(A) Schematic representation of the RIG-I protein. The RIG-I HD-CTD (ΔCARDs) 
construct is boxed. 
(B) Overall structure of the RIG-I (ΔCARDs) dsRNA complex. Starting from the N 
terminus: HEL1 is in green, the bridge between the two helicase domains gray, HEL2 
blue, the insertion domain (HEL2i) cyan, the pincer region (P) red, and the C-terminal 
domain (CTD) orange. The top strand of the RNA duplex (dsRNA10) is in magenta and 
the bottom strand pink.  
(C) Side view showing the RNA interface with the central groove of RIG-I (ΔCARDs). 
This is a 90° rotation along the y axis relative to the orientation shown in (B). 
(D) Solvent-accessible electrostatic surface views of RIG-I (ΔCARDs), shown with ± 10 
kbT/ec. 
____________ 
*Reprinted with permission from “Structural insights into RNA recognition by RIG-I” 
by D. Luo, S.C. Ding, A. Vela, A. Kohlway, B.D. Lindenbach, and A.M. Pyle. 2011. 
Cell 147: 409-422. Copyright (2011) by Elsevier. 
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Figure 5.4 Structural model of dsRNA-mediated activation of RIG-I (114)*.  
RIG-I is an intracellular nanomachine that recognizes viral RNAs and elicits an innate 
immune response. In the absence of viral infection, RIG-I is autoinhibited, and the 
access of the CARDs, which are important for signal transduction, is limited sterically 
by the neighbouring helicase insertion domain (Hel2i) and the C2–Hel1 linker. The CTD 
recognizes 5'-triphosphate in dsRNA and initiates the binding of the helicase domains to 
the first turn of the double helix, where an ATP-binding site is assembled. ATP 
hydrolysis is required for the migration of RIG-I along the duplex RNA. The liberated 
CARDs bind Lys63 polyubiquitin chains and stimulate the massive aggregation of the 
mitochondrial protein MAVS, which ultimately leads to the induction of type I 
interferons and other antiviral molecules. C1/C2, CARD1/CARD2, caspase activation 
and recruitment domain 1/2; CTD, carboxy-terminal domain; dsRNA, double-stranded 
RNA; Hel1/Hel2, helicase 1/helicase 2; P, pincer domain. 
____________ 
*Reprinted with permission from “Structural insights into the activation of RIG-I, a 
nanosensor for viral RNAs” by Q.-X. Jiang, and Z.J. Cheng. 2012. EMBO reports, 13: 7-
8. Copyright (2012) by Nature Publishing Group. 
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In addition to these ligand-bound structures, the structure of full-length RIG-I 
from duck in ligand-free state was also obtained (113). Comparison of these structures 
reveals a clear conformational rearrangement induced by RNA binding. 
Based on these achievements, a revised model of RIG-I activation has been 
proposed (Figure 5.4). In the absence of RNA, full-length RIG-I adopts an autorepressed 
conformation in which the two CARDs interact with the HEL2i, preventing CARDs 
from polyubiquitination by TRIM25 that is critical for RIG-I activation. The 
autoinhibited RIG-I is open and flexible for the helicase domain and the CTD which was 
disordered in the crystal structure of full-length duck RIG-I in ligand-free state (113). 
The CTD is presumably available for viral RNA detection and the initial capture of 5'-
ppp dsRNA would then recruit the RNA to the helicase. Subsequent cooperative binding 
of dsRNA and ATP causes a conformational rearrangement which is coordinated by the 
pincer motif, bringing the three helicase subdomains into close contact and creating a 
high-affinity complex between the helicase domain and the dsRNA. This dramatic 
change in conformation results in the releasing of the CARDs from their autorepressed 
state, allowing for modifications and interaction with IPS-1 (110,113). RIG-I may 
translocate along the RNA in an ATP-dependent manner (115) and RNA-induced 
dimerization or oligomerization of RIG-I may also be involved in the activation process 
(88). 
Although those studies discussed above already made important discovers in 
understanding the mechanism of RIG-I activation, we have to notice that the dsRNA 
ligands they used in cocrystallization with RIG-I were all short dsRNA lacking the 5'-
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ppp group, which may have low capacity for the induction of type I IFNs. Therefore it 
would still be worthwhile to continue our work in this Chapter. The crystals described in 
this study would provide more information if their structure can be determined. First, the 
24-bp dsRNA we use to cocrystallize with RIG-I HD-CTD is longer than all those the 
other researchers used. It is twice the length of RIG-I footprint on dsRNA which is 9-10 
bp and RIG-I forms a 2:1 complex with one protein binds to each end of the RNA. This 
may help us to understand the RNA-induced dimerization of RIG-I. Second, the 14-bp 
GC-rich dsRNA we use for HD-CTD cocrystallization contains the 5'-ppp group, which 
is crucial for RIG-I signaling induction. If structure of this complex can be obtained, we 
can compare it with the crystal structure of the non-ppp dsRNA complex to find out the 
differences between the two binding interactions and two RIG-I conformations. 
Furthermore, in our study, we use ATP instead of analogs, which may result in a 
different RIG-I conformational change because of the energy from ATP hydrolysis.  
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CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
A better understanding of the function and activity of RIG-I as a critical antiviral 
innate immune receptor requires knowledge of the mechanisms associated with viral 
RNA sensing and signaling. There are three main questions that we would like to 
address in this study: 1) What are the structural features of viral RNA recognized by 
RIG-I? 2) How does RIG-I recognize viral RNA? 3) How does RNA binding activate 
RIG-I? To answer these questions, we applied both biochemical approaches and X-ray 
crystallography to analyze the interactions between RIG-I and various RNA. The results 
are summarized as follows. 
To explore the RNA ligand specificity of RIG-I receptor, we performed 
biochemical binding studies on RIG-I CTD which is the domain that directly interacts 
with viral RNA. Gel filtration chromatography and EMSA experiments showed that 
RIG-I CTD binds to dsRNA with and without 5'-ppp group, as well as 5'-ppp ssRNA. 
Duplex RNA with both GC-rich and AU-rich sequences bind to RIG-I CTD very well, 
indicating that RIG-I recognizes RNA in a sequence independent manner. RIG-I CTD 
also binds to 5'- or 3'-overhanging dsRNA with 5'-ppp. However, SAP treatment of the 
overhanging dsRNA which removes the 5'-ppp dramatically reduced their binding with 
RIG-I CTD. Consistent with this, chemically synthesized dsRNA with 5'-overhangs 
failed to bind RIG-I CTD, while dsRNA with 3'-overhangs binds to RIG-I CTD with 
greatly reduced affinity. These demonstrated that the 5'-ppp group increases the affinity 
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of the dsRNA for RIG-I. The fact that RIG-I CTD does not bind to dsDNA also confirms 
that RIG-I is a viral RNA receptor. 
Based on the elution profiles of gel filtration chromatography, we estimated that 
RIG-I CTD forms 2:1 complexes with blunt-ended dsRNA with or without 5'-ppp. AUC 
sedimentation velocity and equilibrium analyses confirmed the stoichiometry of RIG-I 
CTD binding to 5'-ppp dsRNA to be 2:1. In addition, a titration study by gel filtration 
chromatography analyzing the non-ppp dsRNA with increasing amount of RIG-I CTD 
from 1:1 to 4:1 also showed that the saturating ratio is 2:1. 
Equilibrium and kinetic binding studies by SPR were conducted to determine the 
affinity and kinetic properties of RIG-I binding to 5'-ppp dsRNA, 5'-ppp ssRNA, and 
dsRNA without 5'-ppp. All three kinds of RNA bind to RIG-I CTD with high affinities. 
Among them, 5'-ppp dsRNA exhibits the highest binding affinity at 0.32 ± 0.05 nM for 
RIG-I and shows a slow association rate and a slow dissociation rate, indicating the 
requirement of conformational change in the interaction. In contrast, the binding of the 
non-ppp dsRNA shows faster association and dissociation rates.  
The SPR results suggest that 5'-ppp dsRNA should be a more potent stimulator 
of RIG-I, and this has been verified by IFN-β luciferase reporter gene assays. The three 
types of RNA tested, non-ppp dsRNA, 5'-ppp dsRNA and ssRNA, are all able to 
stimulate RIG-I signaling activities in HEK 293T cells, and the 5'-ppp dsRNA has the 
highest activity when used at low concentration. 
X-ray crystallography was used to obtain structural information in detail for 
understanding the binding interactions between RIG-I and dsRNA. We have crystallized 
  
152 
the three dsRNA complexes of human RIG-I CTD, two with 5'-ppp dsRNA and one with 
non-ppp dsRNA. In all structures, each dsRNA adopts a standard A-form double helical 
structure and recruits two CTD molecules on each terminal symmetrically. For 5'-ppp 
dsRNA binding, the contacts are made primarily through electrostatic interactions with a 
few nucleotides at the 5'-end and especially the 5'-ppp group which extensively interacts 
with the CTD at a positively charged cleft. On the other hand, the dsRNA without 5'-ppp 
interacts with the CTD through the first few base-paring nucleotides at both 5'- and 5'-
ends. Comparison of the structures of RIG-I CTD bound to these dsRNA revealed that 
the orientation of two types of RNA relative to the protein is dramatically different. The 
dsRNA without 5'-ppp lacks the extensive interactions between the 5'-ppp moiety and 
the positively charged cleft, and it has to compensate by swinging towards the protein by 
about 15° to increase its contacts with the protein. Structural-based mutagenesis 
experiments revealed distinct but overlapping amino acids on the binding surface are 
involved in substrate recognition, and validated the importance of key residues in RNA 
recognition and RIG-I signaling. These studies demonstrated that RIG-I CTD is a 
versatile RNA-binding module using its positively charged binding surface to recognize 
different forms of RNA ligands. The diversity of virus types that can be detected by 
RIG-I may be explained by this versatility of substrate selection and recognition. 
Comparing the crystal structures of RIG-I and LGP2 CTD complexes suggests 
that the two proteins use similar binding surfaces to interact with RNA, although the 
RNA is shifted in orientation. The dsRNA in LGP2 complex rotates along its helical axis 
and swings towards the CTD by about 15° relative to the position of the non-ppp dsRNA 
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in the RIG-I CTD complex. A similar CTD binding surface is also likely to be involved 
in MDA5 interaction with dsRNA. With no luck in crystallizing MDA5 CTD complex 
with dsRNA, we examine this prediction by a NMR titration study. The residues with 
perturbed chemical shift resonances were picked out as being involved in the interaction 
with RNA, and mapped onto the surface of MDA5 CTD crystal structure. The results 
showed a similar binding surface as RIG-I and LGP2 CTDs with positively charged 
residues. However, we notice that the critical residues involved in 5'-ppp moiety binding 
of RIG-I CTD are lacking in MDA5 and LGP2, suggesting a structural basis for the 
differences in RLR ligand specificity. 
In the last part of this work, we also attempted to analyze the role of RIG-I 
helicase domain in RNA interaction and RIG-I activation by structural method. We 
expressed the human RIG-I HD-CTD in both baculovirus-insect cells system, and 
bacteria and purified the protein in complex with dsRNA. We crystallized HD-CTD 
bound to a 24-bp dsRNA without 5'-ppp as a 2:1 complex, in the presence of ATP. In 
addition, we also crystallized HD-CTD in complex with a 14-bp 5'-ppp dsRNA in the 
presence of either ATP or a RIG-I inhibitor EGCG. Unfortunately, because all these 
crystals were small and diffracted weakly, their crystal structures could not be obtained.  
Nonetheless, there are several other groups have independently determined the crystal 
structures of the helicase or HD-CTD in complex with short non-ppp dsRNA (110-113), 
provide insights into the mechanisms of RNA-induced ATP-dependent conformational 
change and activation of RIG-I. However, it would still be informative if the structures 
of the crystals described in this work could be determined in the future, because 
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currently there is no available structure of a 5'-ppp dsRNA bound helicase, which might 
show a distinct conformation from that of a non-ppp dsRNA bound structure. 
Furthermore, we still lack a crystal structure of full-length RIG-I in complex with which 
we could compare with the structure of full-length protein alone (113) to confirm the 
current RIG-I activation model.  
The studies in this dissertation have been focused on RIG-I, the prototypical 
protein of RLRs. Questions regarding the pathogen recognition and signaling of other 
RLRs still remain unresolved. Future investigations would seek to define the RNA 
ligand specificity of MDA5 and LGP2, using the effective biochemical approaches 
described in this study. The activation mechanism of MDA5 is also of interest because it 
does not seem to be regulated by the autoinhibition mode. On the other hand, the 
CARDs-lacking LGP2 does not have a direct signaling activity. The positive and 
negative regulation of MDA5 and RIG-I signaling, respectively, suggest multiple 
functions of LGP2 that are undetermined. The general role of LGP2 in RLR-mediated 
antiviral signaling, and how it regulates the RLRs, whether by competing with ligand 
RNA binding or by direct interaction with RIG-I and MDA5, would be another 
important direction for future research. 
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